<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        33-51-97
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EPREX 3000IU-0.3ML PREFILLED SYRINGE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EPOETIN ALFA
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        406.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="JANSSEN-CILAG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            JANSSEN-CILAG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B03XA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EPREX contains the active substance epoetin alfa - a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen). Epoetin alfa is a copy of the human protein erythropoietin (ee-rith-roe-po-eh-tin) and acts in the same way.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>EPREX is used to treat symptomatic anaemia caused by kidney disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in children on haemodialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults on haemodialysis or peritoneal dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in severely anaemic adults not yet undergoing dialysis.</p><p>&nbsp;</p><p>If you have kidney disease, you may be short of red blood cells if your kidney does not produce enough erythropoietin (necessary for red cell production). EPREX is prescribed to stimulate your bone marrow to produce more red blood cells.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>EPREX is used to treat anaemia in adults receiving chemotherapy for solid tumours, </strong>malignant lymphoma or multiple myeloma (bone marrow cancer) who may have a need for a blood transfusion. EPREX can reduce the need for a blood transfusion in these patients.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>EPREX is used in moderately anaemic adults who donate some of their blood before </strong>surgery, so that it can be given back to them during or after the operation. Because EPREX stimulates the production of red blood cells, doctors can take more blood from these people.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>EPREX is used in moderately anaemic adults about to have major orthopaedic surgery </strong><em>(for example hip or knee replacement operations)</em>, to reduce the potential need for&nbsp; blood transfusions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use</strong> <strong>EPREX</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic (hypersensitive) </strong>to epoetin alfa or any of the other ingredients of EPREX (listed in section&nbsp;6, <em>Contents of the pack and other information</em>).</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have been diagnosed with Pure Red Cell Aplasia </strong>(the bone marrow cannot produce enough red blood cells) after previous treatment with any product that stimulates red blood cell production (including EPREX). See section&nbsp;4, <em>Possible side effects</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you have high blood pressure </strong>not properly controlled with medicines.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To stimulate the production of your red blood cells (so that doctors can take more blood from you<strong>) if you cannot have transfusions with your own blood</strong> during or after surgery.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are due to have major elective orthopaedic surgery </strong>(such as hip or knee surgery), and you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe heart disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe disorders of the veins and arteries</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently had a heart attack or stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; can&rsquo;t take medicines to thin the blood</p><p>&nbsp;</p><p>EPREX may not be suitable for you. Please discuss with your doctor. While on EPREX, some people need medicines to reduce the risk of blood clots<strong>. If you can&rsquo;t take medicines that prevent blood clotting, you must not have EPREX.</strong></p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p><strong>Take special care with EPREX</strong></p><p>&nbsp;</p><p><strong>EPREX and other products that stimulate red cell production may increase the risk of developing blood clots in all patients. This risk may be higher if you have other risk factors</strong> for developing blood clots <em>(for example, if you have had a blood clot in the past or are overweight, have diabetes, have heart disease or you are off your feet for a long time because of surgery or illness). </em>Please tell your doctor about any of these things. Your doctor will help you to decide if EPREX is suitable for you.</p><p>&nbsp;</p><p><strong>It</strong><strong> is important to tell your doctor</strong> if any of the following apply to you<strong>. </strong>You may still be able to use EPREX, but discuss it with your doctor first.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you know you suffer</strong>, or have suffered, from:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>high blood pressure;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>epileptic seizures or fits</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>liver disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anaemia from other causes</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>porphyria (a rare blood disorder)</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are a patient with chronic renal failure</strong>, and particularly if you do not respond properly to EPREX, your doctor will check your dose of EPREX because repeatedly increasing your dose of EPREX if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are a cancer patient </strong>be aware that products that stimulate red blood cell production (like EPREX) may act as a growth factor and therefore in theory may affect the progression of your cancer.<strong> Depending on your individual situation a blood transfusion may be preferable. Please discuss this with your doctor.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are a cancer patient, </strong>be aware that use of EPREX may be associated with shorter</p><p>survival and a higher death rate in head and neck, and metastatic breast cancer patients who are</p><p>receiving chemotherapy.</p><p><strong>&nbsp;</strong></p><p><strong>Take special care with other products that stimulate red blood cell production:</strong></p><p>&nbsp;</p><p>EPREX is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does. Your healthcare professional will always record the exact product you are using.</p><p>&nbsp;</p><p>If you are given a product in this group other than EPREX during your treatment, speak to your doctor or pharmacist before using it.</p><p>&nbsp;</p><p><strong>Other medicines and EPREX</strong></p><p>&nbsp;</p><p>EPREX does not normally react with other medicines but please tell your doctor if you are using (or have recently used) any other medicines &ndash; including medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>If you are taking a drug called cyclosporin</strong> (used e.g. after kidney transplants), your doctor may order blood tests to check the level of cyclosporin while you are taking EPREX.</p><p>&nbsp;</p><p><strong>Iron supplements and other blood stimulants</strong> may increase the effectiveness of EPREX. Your doctor will decide if it is right for you to take them.</p><p>&nbsp;</p><p><strong>If you visit a hospital, clinic or family doctor</strong>, tell them you are having EPREX treatment. It may affect other treatments or test results.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p><strong>It is important to tell your doctor</strong> if any of the following apply to you. You may still be able to use EPREX, but discuss it with your doctor first.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are pregnant</strong>, or think you may be pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are breast feeding.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always use this medicine exactly as your doctor has told you.</strong> Check with your doctor if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>Your doctor has carried out blood tests</strong> and decided you need EPREX.</p><p>&nbsp;</p><p>EPREX may be given by injection:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Either </strong>into a vein or a tube that goes into a vein (intravenously)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Or </strong>under the skin (subcutaneously).</p><p>&nbsp;</p><p>Your doctor will decide how EPREX will be injected. Usually the injections will be given to you by a doctor, nurse or other health care professional. Some people, depending on why they need EPREX treatment, may later learn how to inject themselves under the skin: see <em>Instructions on how to inject EPREX yourself.</em></p><p><em>&nbsp;</em></p><p>EPREX should not be used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; after the expiry date on the label and outer carton</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know, or think that it may have been accidentally frozen, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if there has been a refrigerator failure.</p><p>&nbsp;</p><p>The dose of EPREX you receive is based on your bodyweight in kilograms. The cause of your anaemia is also a factor in your doctor deciding the correct dose.</p><p>&nbsp;</p><p><strong>Your doctor will monitor your blood pressure </strong>regularly while you are using EPREX.</p><p>&nbsp;</p><p><strong>People with kidney disease</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will maintain your haemoglobin level between 10 and 12&nbsp;g/dl as a high haemoglobin level may increase the risk of blood clots and death.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The usual starting dose</strong> of EPREX for adults and children is 50 International Units (IU) per kilogram (/kg) of bodyweight given three times a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients on peritoneal dialysis EPREX may be given twice a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For adults and children EPREX is given as an injection either into a vein or a tube that goes into a vein. When this access (via a vein or tube) is not readily available, your doctor may decide that EPREX should be injected under the skin (subcutaneously). This includes patients on dialysis and patients not yet on dialysis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will order regular blood tests to see how your anaemia is responding and may adjust the dose, usually no more frequently than every four weeks.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once your anaemia has been corrected, your doctor will continue to check your blood regularly. Your EPREX dose and frequency of administration may be further adjusted to maintain your response to treatment. Your doctor will use the lowest effective dose to control the symptoms of your anemia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not respond adequately to EPREX, your doctor will check your dose and will inform you if you need to change doses of EPREX.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are on a more extended dosing interval (greater than once weekly) of EPREX, you may not maintain adequate haemoglobin levels and you may require an increase in EPREX dose or frequency of administration.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during EPREX treatment to make it more effective.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are having dialysis treatment when you begin treatment with EPREX, your dialysis regime may need to be adjusted. Your doctor will decide this.</p><p>&nbsp;</p><p><strong>Adults on chemotherapy</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may initiate treatment with EPREX if your haemoglobin is 10&nbsp;g/dl or less.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will maintain your haemoglobin level between 10 and 12&nbsp;g/dl as a high haemoglobin level may increase the risk of blood clots and death.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The starting dose is <strong>either</strong> 150&nbsp;IU per kilogram bodyweight three times a week or 450&nbsp;IU per kilogram bodyweight once a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EPREX is given by injection under the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will order blood tests, and may adjust the dose, depending on how your anaemia responds to EPREX treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during EPREX treatment to make it more effective.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will usually continue EPREX treatment for one month after the end of chemotherapy.</p><p>&nbsp;</p><p><strong>Adults donating their own blood</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The usual dose</strong> is 600&nbsp;IU per kilogram bodyweight twice a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EPREX is given by injection into a vein immediately after you have donated blood for 3&nbsp;weeks before your surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during EPREX treatment to make it more effective.</p><p>&nbsp;</p><p><strong>Adults scheduled for major orthopaedic surgery</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The recommended dose</strong> is 600&nbsp;IU per kilogram bodyweight once a week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EPREX is given by injection under the skin each week for three weeks before surgery and on the day of surgery.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If there is a medical need to reduce the time before your operation, you will be given a daily dose of 300&nbsp;IU/kg for up to ten days before surgery, on the day of surgery and for four days immediately afterwards.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If blood tests show your haemoglobin is too high before the operation, the treatment will be stopped.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may be given iron supplements before and during EPREX treatment to make it more effective.</p><p>&nbsp;</p><p><strong>Instructions on how to inject EPREX yourself</strong></p><p><strong>&nbsp;</strong></p><p>When treatment starts, EPREX is usually injected by medical or nursing staff. Later, your doctor may suggest that you or your caregiver learn how to inject EPREX under the skin (<em>subcutaneously</em>) yourself.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not attempt to inject yourself unless you have been trained to do so by your doctor or nurse.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Always use EPREX exactly as instructed by your doctor or nurse.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Only use EPREX if it has been stored correctly &ndash; see section&nbsp;5, <em>How to Store EPREX</em>.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Before use, leave the EPREX syringe&nbsp; to stand until it reaches room temperature. This usually takes between 15 and 30&nbsp;minutes. </strong></p><p><em><u>&nbsp;</u></em></p><p><strong>Only take one dose of EPREX from each syringe .</strong></p><p>&nbsp;</p><p>If EPREX is injected under the skin (subcutaneously), the amount injected is not normally more than one millilitre (1&nbsp;ml) in a single injection.</p><p>&nbsp;</p><p>EPREX is given alone and not mixed with other liquids for injection.</p><p>&nbsp;</p><p><strong>Do not shake EPREX syringes.</strong> Prolonged vigorous shaking may damage the product. If the product has been shaken vigorously, don&rsquo;t use it.</p><p><strong>&nbsp;</strong></p><p><strong>How to inject yourself using a pre-filled syringe:</strong></p><p>&nbsp;</p><p>The pre-filled syringes are fitted with the PROTECS<sup>&trade;</sup> needle guard device to help prevent needle stick injuries after use. This is indicated on the packaging.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_6" o:spid="_x0000_s1030"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:198pt;margin-top:21.95pt;width:27pt;height:9pt;z-index:251655680;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>BODY</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_3"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:225pt;margin-top:21.45pt;width:36pt;height:18pt;
 z-index:251652608;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>VIEWING<br />WINDOW</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_2"
 o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:315pt;margin-top:20.45pt;width:27pt;height:18pt;
 z-index:251651584;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQDXm/APcwIAANAEAAAOAAAAZHJzL2Uyb0RvYy54bWysVMtu2zAQvBfoPxC8O5JV52EjcqA4cFEg
aAIkRc40RcUCJC5L0pbcov/eIWUlbdpTUR/o5T65s7O6vOrbhu2VdTXpnE9PUs6UllTW+jnnXx7X
kwvOnBe6FA1plfODcvxq+f7dZWcWKqMtNaWyDEm0W3Qm51vvzSJJnNyqVrgTMkrDWJFthcfVPiel
FR2yt02SpelZ0pEtjSWpnIP2ZjDyZcxfVUr6u6pyyrMm53ibj6eN5yacyfJSLJ6tMNtaHp8h/uEV
rag1ir6kuhFesJ2t/0jV1tKSo8qfSGoTqqpaqtgDupmmb7p52AqjYi8Ax5kXmNz/Sys/7+8tq8uc
Z5xp0WJEj6r37Jp6lgV0OuMWcHowcPM91JjyqHdQhqb7yrbhH+0w2IHz4QXbkExC+WGWzVNYJExZ
dnEGGdmT12Bjnf+oqGVByLnF6CKiYn/r/OA6uoRajpq6XNdNEy8Ht2os2wtMGeQoqeOsEc5DmfN1
/B2r/RbW6BCsKaQZKgwaFYkzlBULdAAxeIZe4lC/r07Ps+L8dD45K06nk9k0vZgURZpNbtZFWqSz
9Wo+u/5xLDnGJwHKAbIg+X7TR+DP5yOeGyoPgNnSQFNn5LoGGLfo5F5Y8BL4Ydf8HY6qoS7ndJQ4
25L99jd98AddYOWsA89z7r7uhFUA6JMGkcJSjIIdhc0o6F27IoA6xRYbGUUEWN+MYmWpfcIKFqEK
TEJL1Mq5H8WVH7YNKyxVUUQnUN8If6sfjAypA7RhtI/9k7DmOH8P2D7TuAFi8YYGg+8wvmLnqaoj
RwKwA4rgVrhgbSLLjise9vLXe/R6/RAtfwIAAP//AwBQSwMEFAAGAAgAAAAhAPJpv2vfAAAACQEA
AA8AAABkcnMvZG93bnJldi54bWxMj01PwzAMhu9I/IfISFwQSxhT2bqmE2xwG4d9aOesMW1F41RN
unb/HnOCo+1Xj583W42uERfsQu1Jw9NEgUAqvK2p1HA8fDzOQYRoyJrGE2q4YoBVfnuTmdT6gXZ4
2cdSMIRCajRUMbaplKGo0Jkw8S0S375850zksSul7czAcNfIqVKJdKYm/lCZFtcVFt/73mlINl0/
7Gj9sDm+b81nW05Pb9eT1vd34+sSRMQx/oXhV5/VIWens+/JBtEw41lxl6hhphYgOJDMZ7w4a3hJ
FiDzTP5vkP8AAAD//wMAUEsBAi0AFAAGAAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAA
AAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA15vwD3MCAADQBAAADgAAAAAA
AAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwECLQAUAAYACAAAACEA8mm/a98AAAAJAQAADwAA
AAAAAAAAAAAAAADNBAAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAAEAAQA8wAAANkFAAAAAA==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>NEEDLE COVER</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_4"
 o:spid="_x0000_s1028" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:4in;margin-top:94.45pt;width:36pt;height:9pt;
 z-index:251653632;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQB1lFKrcAIAANAEAAAOAAAAZHJzL2Uyb0RvYy54bWysVMtu2zAQvBfoPxC8O5JT5SVEDhQHLgoE
TYCkyJmmqFiAxGVJ2pJb9N87pKykTXsq6gO93Cd3dlaXV0PXsp2yriFd8PlRypnSkqpGPxf8y+Nq
ds6Z80JXoiWtCr5Xjl8t3r+77E2ujmlDbaUsQxLt8t4UfOO9yZPEyY3qhDsiozSMNdlOeFztc1JZ
0SN71ybHaXqa9GQrY0kq56C9GY18EfPXtZL+rq6d8qwtON7m42njuQ5nsrgU+bMVZtPIwzPEP7yi
E41G0ZdUN8ILtrXNH6m6RlpyVPsjSV1Cdd1IFXtAN/P0TTcPG2FU7AXgOPMCk/t/aeXn3b1lTVXw
jDMtOozoUQ2eXdPAsoBOb1wOpwcDNz9AjSlPegdlaHqobRf+0Q6DHTjvX7ANySSU2ckZ5sWZhGk+
zz5ARvbkNdhY5z8q6lgQCm4xuoio2N06P7pOLqGWo7apVk3bxsveLVvLdgJTBjkq6jlrhfNQFnwV
f4dqv4W1OgRrCmnGCqNGReKMZUWODiAGz9BLHOr3Jbopz04uZqflyXyWzdPzWVmmx7ObVZmWabZa
XmTXPw4lp/gkQDlCFiQ/rIcI/HlEIqjWVO0Bs6WRps7IVQMwbtHJvbDgJfDDrvk7HHVLfcHpIHG2
Ifvtb/rgD7rAylkPnhfcfd0KqwDQJw0ihaWYBDsJ60nQ225JAHWOLTYyigiwvp3E2lL3hBUsQxWY
hJaoVXA/iUs/bhtWWKqyjE6gvhH+Vj8YGVIHaMNoH4cnYc1h/h6wfaZpA0T+hgaj7zi+cuupbiJH
XlEEt8IFaxNZdljxsJe/3qPX64do8RMAAP//AwBQSwMEFAAGAAgAAAAhACQOTpfgAAAACwEAAA8A
AABkcnMvZG93bnJldi54bWxMj8FOwzAQRO9I/IO1SFwQdYggpCFOBS3c4NBS9byNTRIRryPbadK/
ZznBcWdGs2/K1Wx7cTI+dI4U3C0SEIZqpztqFOw/325zECEiaewdGQVnE2BVXV6UWGg30dacdrER
XEKhQAVtjEMhZahbYzEs3GCIvS/nLUY+fSO1x4nLbS/TJMmkxY74Q4uDWbem/t6NVkG28eO0pfXN
Zv/6jh9Dkx5ezgelrq/m5ycQ0czxLwy/+IwOFTMd3Ug6iF7Bw2PGWyIbeb4EwYnsPmflqCBNsiXI
qpT/N1Q/AAAA//8DAFBLAQItABQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAAAAAAAAAAAAAAAAA
AABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhADj9If/WAAAAlAEAAAsAAAAAAAAA
AAAAAAAALwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAHWUUqtwAgAA0AQAAA4AAAAAAAAA
AAAAAAAALgIAAGRycy9lMm9Eb2MueG1sUEsBAi0AFAAGAAgAAAAhACQOTpfgAAAACwEAAA8AAAAA
AAAAAAAAAAAAygQAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAABAAEAPMAAADXBQAAAAA=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>NEEDLE<br />&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_5"
 o:spid="_x0000_s1029" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:198pt;margin-top:94.45pt;width:36pt;height:14pt;
 z-index:251654656;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>LABEL<br />&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_7"
 o:spid="_x0000_s1031" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:135pt;margin-top:94.95pt;width:45pt;height:18pt;
 z-index:251656704;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>NEEDLE GUARD WINGS<br />&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_8"
 o:spid="_x0000_s1032" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:90pt;margin-top:94.95pt;width:36pt;height:18pt;
 z-index:251657728;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQDmXD+KcQIAANAEAAAOAAAAZHJzL2Uyb0RvYy54bWysVF1P2zAUfZ+0/2D5vSTtCpSIFIWiTpPQ
QIKJZ9dxaKTE17PdJt20/75jp4GN7WlaH9zr++l77rm5vOrbhu2VdTXpnE9PUs6UllTW+jnnXx7X
kwVnzgtdioa0yvlBOX61fP/usjOZmtGWmlJZhiTaZZ3J+dZ7kyWJk1vVCndCRmkYK7Kt8Lja56S0
okP2tklmaXqWdGRLY0kq56C9GYx8GfNXlZL+rqqc8qzJOd7m42njuQlnsrwU2bMVZlvL4zPEP7yi
FbVG0ZdUN8ILtrP1H6naWlpyVPkTSW1CVVVLFXtAN9P0TTcPW2FU7AXgOPMCk/t/aeXn/b1ldZlz
DEqLFiN6VL1n19SzRUCnMy6D04OBm++hxpRHvYMyNN1Xtg3/aIfBDpwPL9iGZBLK+ek55sWZhGk2
W5xBRvbkNdhY5z8qalkQcm4xuoio2N86P7iOLqGWo6Yu13XTxMvBrRrL9gJTBjlK6jhrhPNQ5nwd
f8dqv4U1OgRrCmmGCoNGReIMZUWGDiAGz9BLHOr3Fbopzk8vJmfF6XQyn6aLSVGks8nNukiLdL5e
XcyvfxxLjvFJgHKALEi+3/QD8B9GPDdUHgCzpYGmzsh1DTBu0cm9sOAl8MOu+TscVUNdzukocbYl
++1v+uAPusDKWQee59x93QmrANAnDSKFpRgFOwqbUdC7dkUAdYotNjKKCLC+GcXKUvuEFSxCFZiE
lqiVcz+KKz9sG1ZYqqKITqC+Ef5WPxgZUgdow2gf+ydhzXH+HrB9pnEDRPaGBoPvML5i56mqI0cC
sAOK4Fa4YG0iy44rHvby13v0ev0QLX8CAAD//wMAUEsDBBQABgAIAAAAIQDy5fhE3gAAAAsBAAAP
AAAAZHJzL2Rvd25yZXYueG1sTE9BTsMwELwj8Qdrkbgg6mCpVRPiVNDCDQ4tVc/bxE2ixuvIdpr0
92xPcJvZGc3O5KvJduJifGgdaXiZJSAMla5qqdaw//l8XoIIEanCzpHRcDUBVsX9XY5Z5Ubamssu
1oJDKGSooYmxz6QMZWMshpnrDbF2ct5iZOprWXkcOdx2UiXJQlpsiT802Jt1Y8rzbrAaFhs/jFta
P232H1/43dfq8H49aP34ML29gohmin9muNXn6lBwp6MbqAqiY75MeEu8gTQFwQ41V3w5MlDzFGSR
y/8bil8AAAD//wMAUEsBAi0AFAAGAAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAAAAAA
AFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAAAAAA
AAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA5lw/inECAADQBAAADgAAAAAAAAAA
AAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwECLQAUAAYACAAAACEA8uX4RN4AAAALAQAADwAAAAAA
AAAAAAAAAADLBAAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAAEAAQA8wAAANYFAAAAAA==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>PLUNGER HEAD</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_9"
 o:spid="_x0000_s1033" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:90pt;margin-top:23.45pt;width:36pt;height:9pt;
 z-index:251658752;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>PLUNGER</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_11"
 o:spid="_x0000_s1035" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:70.5pt;margin-top:4.95pt;width:189pt;height:9pt;
 z-index:251660800;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Figure 1 shows what the pre-filled syringe looks like.</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_10"
 o:spid="_x0000_s1034" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:124.5pt;margin-top:21.45pt;width:63pt;height:18pt;
 z-index:251659776;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQBEHGvrcgIAANIEAAAOAAAAZHJzL2Uyb0RvYy54bWysVFFP2zAQfp+0/2D5vSStoJSIFIWiTpMQ
IMHEs+s4NFLi82y3STftv++z08DG9jSNB3O+O3+X++67Xl71bcP2yrqadM6nJylnSksqa/2S8y9P
68mCM+eFLkVDWuX8oBy/Wn78cNmZTM1oS02pLAOIdllncr713mRJ4uRWtcKdkFEawYpsKzyu9iUp
reiA3jbJLE3nSUe2NJakcg7emyHIlxG/qpT091XllGdNzvFtPp42nptwJstLkb1YYba1PH6G+Iev
aEWtUfQV6kZ4wXa2/gOqraUlR5U/kdQmVFW1VLEHdDNN33XzuBVGxV5AjjOvNLn/Byvv9g+W1SVm
B3q0aDGjJ9V7dk09gwv8dMZlSHs0SPQ9/Mgd/Q7O0HZf2Tb8R0MMcUAdXtkNaBLORYoOEZEIzWaL
OWygJ2+PjXX+k6KWBSPnFsOLnIr9rfND6pgSajlq6nJdN028HNyqsWwvMGfIo6SOs0Y4D2fO1/Hv
WO23Z40OjzUFmKHC4FFROkNZkaEDmCEz9BLH+n11dj4rzs8uJvPibDo5naaLSVGks8nNukiL9HS9
uji9/nEsOb5PApUDZcHy/aaP1C/mI58bKg+g2dIgVGfkugYZt+jkQVgoE/xh2/w9jqqhLud0tDjb
kv32N3/Ih2AQ5ayD0nPuvu6EVSDos4aUAOlHw47GZjT0rl0RSJ1ij42MJh5Y34xmZal9xhIWoQpC
QkvUyrkfzZUf9g1LLFVRxCSI3wh/qx+NDNCB2jDap/5ZWHOcvwdtdzTugMjeyWDIHcZX7DxVddRI
IHZgEdoKFyxOVNlxycNm/nqPWW8/RcufAAAA//8DAFBLAwQUAAYACAAAACEARsLSXeAAAAAJAQAA
DwAAAGRycy9kb3ducmV2LnhtbEyPzU7DMBCE70i8g7VIXBB1CKVtQjYVtPQGh/6oZzdxk4h4HdlO
k749ywmOszOa/SZbjqYVF+18YwnhaRKB0FTYsqEK4bDfPC5A+KCoVK0ljXDVHpb57U2m0tIOtNWX
XagEl5BPFUIdQpdK6YtaG+UnttPE3tk6owJLV8nSqYHLTSvjKJpJoxriD7Xq9KrWxfeuNwizteuH
La0e1oePT/XVVfHx/XpEvL8b315BBD2GvzD84jM65Mx0sj2VXrQI8TThLQFhGicgOPA8f+HDCWG+
SEDmmfy/IP8BAAD//wMAUEsBAi0AFAAGAAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAA
AAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEARBxr63ICAADSBAAADgAAAAAA
AAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwECLQAUAAYACAAAACEARsLSXeAAAAAJAQAADwAA
AAAAAAAAAAAAAADMBAAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAAEAAQA8wAAANkFAAAAAA==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>NEEDLE GUARD ACTIVATION CLIPS</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:284.5pt;height:100.5pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/malqahta/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.emz"
  o:title="" croptop="-41385f" cropbottom="-8193f" cropleft="-3774f"
  cropright="-1f"/>
</v:shape><![endif]--><img width="379" height="134" alt="" src="file:///C:/Users/malqahta/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_12"
 o:spid="_x0000_s1036" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:198pt;margin-top:1.25pt;width:36pt;height:14pt;
 z-index:251661824;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Figure 1</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take a syringe out of the refrigerator.</strong> The liquid needs to come to room temperature. Do not remove the syringe&rsquo;s needle cover while allowing it to reach room temperature.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Check the syringe, </strong>to make sure it is the right dose, has not passed its expiry date, is not damaged, and the liquid is clear and not frozen.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Choose an injection site. </strong>Good sites are the top of the thigh and around the tummy (abdomen) but away from the navel. Vary the site from day to day.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Wash your hands. Use an antiseptic swab on the injection site, </strong>to disinfect it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hold the pre-filled syringe by the body of the syringe with the covered needle pointing upward.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not hold by the plunger head, plunger, needle guard wings, or needle cover.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not pull back on the plunger at any time.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not remove the needle cover from the pre-filled syringe until you are ready to inject your EPREX</strong><strong><sup>&Ograve;</sup>/ERYPO</strong><strong><sup>&Ograve;</sup>.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take the cover off the syringe</strong> by holding the barrel and pulling the cover off carefully without twisting it<strong>. </strong>Don&rsquo;t push the plunger, touch the needle or shake the syringe.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not touch the needle activation clips (as indicated by asterisks* in Figure 1) to prevent prematurely covering the needle with the needle guard.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pinch a fold of skin </strong>between your thumb and index finger. Don&rsquo;t squeeze it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Push the needle in fully. </strong>Your doctor or nurse may have shown you how to do this.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Push the plunger with your thumb as far as it will go to inject the entire amount of liquid.</strong>.<strong> </strong>Push it slowly and evenly, keeping the skin fold pinched. <strong>The PROTECS<sup>&trade;</sup> needle guard will not activate unless the entire dose is given. You may hear a click when the PROTECS<sup>&trade;</sup> needle guard has been activated.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>When the plunger is pushed as far as it will go, </strong>take out the needle and let go of the skin.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Slowly take your thumb off the plunger </strong>to allow the syringe to move up until the entire needle is covered by the PROTECS<sup>&trade;</sup> needle guard.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>When the needle is pulled out of your skin, there may be a little bleeding at the injection site. This is normal. You can press an antiseptic swab </strong>over the injection site for a few seconds after the injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Dispose of your used syringe</strong> in a safe container &ndash; see section&nbsp;5, <em>How to store EPREX.</em></p><p><em>&nbsp;</em></p><p><strong>If you use more EPREX than you should</strong></p><p><strong>&nbsp;</strong></p><p>Tell the doctor or nurse immediately if you think too much EPREX has been injected. Side effects from an overdose of EPREX are unlikely.</p><p>&nbsp;</p><p><strong>If you forget to use EPREX</strong></p><p>&nbsp;</p><p>Make the next injection as soon as you remember. If you are within a day of your next injection, forget the missed one and carry on with your normal schedule. Do not double up the injections.</p><p>&nbsp;</p><p><strong>If you are a patient with hepatitis C and you receive interferon and ribavirin</strong></p><p><strong>&nbsp;</strong></p><p>You should discuss this with your doctor because a combination of epoetin alfa with interferon and ribavirin has led to a loss of effect and development of a condition called pure red cell aplasia (PRCA), a severe form of anemia, in rare cases. EPREX is&nbsp;not approved in the management of anaemia associated with hepatitis C.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor, nurse or pharmacist.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, EPREX<strong> </strong>can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor or nurse immediately</strong> if you notice any of the effects in this list.</p><p>&nbsp;</p><p><u>Very common side effects</u></p><p>These may affect more than 1&nbsp;person in 10 using EPREX.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Diarrhoea</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Feeling sick in your stomach</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vomiting</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fever</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Respiratory tract congestion, </strong>such as stuffy nose and sore throat, has been reported in patients with kidney disease not yet on dialysis.</p><p><u>&nbsp;</u></p><p><u>Common side effects</u></p><p>These may affect up to 1&nbsp; in 10&nbsp;people&nbsp; using EPREX.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Increased blood pressure. Headaches</strong>, particularly sudden, stabbing migraine-like headaches, <strong>feeling confused or having fits</strong> may be signs of a sudden increase in blood pressure. This requires urgent treatment. Raised blood pressure may require treatment with drugs (or adjustment to any drugs you already take for high blood pressure).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots</strong> (including deep vein thrombosis and embolism) that may require urgent treatment. You may have <strong>chest pain, breathlessness, and painful swelling and redness, usually in the leg</strong>&nbsp; as symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cough</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Skin rashes, which may result from an allergic reaction.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Bone or muscle pain</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Flu-like symptoms</strong>, such as headache, aches and pains in the joints, feeling of weakness, chills, tiredness and dizziness. These may be more common at the start of treatment. If you have these symptoms during injection into the vein, a slower delivery of the injection may help to avoid them in the future.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Redness, burning and pain at the site of injection</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swelling of the ankles, feet or fingers</strong></p><p><u>Uncommon side effects</u></p><p>These may affect up to 1 in 100&nbsp;people using EPREX.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>High levels of blood potassium</strong> which can cause abnormal heart rhythm (this is a very common side effect in patients on dialysis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fits</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nose or airway congestion</strong></p><p>&nbsp;</p><p><u>Very rare side effects</u></p><p>These may affect&nbsp; up to 1&nbsp; in 10,000&nbsp;people using EPREX.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Symptoms of pure red cell aplasia (PRCA)</strong></p><p>&nbsp;</p><p>PRCA means the bone marrow does not make enough red blood cells. PRCA causes <strong>sudden and severe anaemia. The symptoms are:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>unusual tiredness,</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>feeling dizzy,</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>breathlessness.</strong></p><p>&nbsp;</p><p>PRCA has been very rarely reported mostly in patients with kidney disease after months to years of treatment with EPREX and other products that stimulate red blood cell production.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increase in levels of small blood cells (called platelets), which are normally involved in the formation of a blood clot may occur, particularly when starting treatment. Your doctor will check on this.</p><p>&nbsp;</p><p>If you are receiving haemodialysis:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots</strong> (thrombosis) may form in your dialysis shunt. This is more likely if you have low blood pressure or if your fistula has complications.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood clots</strong> may also form in your haemodialysis system. Your doctor may decide to increase your heparin dose during dialysis.</p><p><strong>&nbsp;</strong></p><p><strong>Tell your doctor or nurse<em> </em>immediately</strong> if you are aware of any of these effects, or if you notice any other effects while you are receiving treatment with EPREX<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><u>Reporting of side effects </u></p><p>If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Keep this medicine out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Do not use this medicine after the expiry date, which is stated on the box and on the label after the letters EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator between &nbsp;(2&deg;C and 8&deg;C)-( 36&ordm;F to 46&ordm;F) away from the freezer compartment , EPREX syringes that are being used or about to be use can be kept at room temprature &nbsp;</p><p>( Not above 25&deg;C) for a maximum single period of 7 days.</p><p>&nbsp;</p><p>Do not freeze or shake.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>Do not use this medicine if you notice that the seal is broken or if the liquid is coloured or you can see particles floating in it. In the event of either being observed, discard the medicinal product.</p><p>&nbsp;</p><p><strong>Do not throw away any medicines via waste water or household waste.</strong> Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What EPREX contains:</strong></p><p><strong>&nbsp;</strong></p><p><strong>The active substance is:</strong> Epoetin alfa (for quantity see the table below).</p><p><strong>The other ingredients are:</strong> Polysorbate 80, sodium chloride, sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, glycine and water for injections.</p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg), per dose i.e. essentially &ldquo;sodium free.&rdquo;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                EPREX is presented as a solution for injection in pre-filled syringe. The pre-filled syringes are fitted with the PROTECS™ needle guard device (see the table below).. EPREX is a clear, colourless solution.

Presentation	Corresponding Presentations in Quantity/Volume for each Strength	Amount of
epoetin alfa
Packs of 6 single pre-filled syringes with PROTECS™ needle guard device	2,000 IU/ml:
1,000 IU/0.5 ml

4,000 IU/ml:
2,000 IU/0.5 ml

10,000 IU/ml:
3,000 IU/0.3 ml
4,000 IU/0.4 ml
5,000 IU/0.5 ml
6,000 IU/0.6 ml
8,000 IU/0.8 ml

10,000 IU/1 ml	
8.4 micrograms


16.8 micrograms


25.2 micrograms
33.6 micrograms
42.0 micrograms
50.4 micrograms
67.2 micrograms

84.0 micrograms 
	Packs of 1 single pre-filled syringe with PROTECS™ needle guard device
		20,000 IU/0.5 ml
	30,000 IU/0.75 ml
40,000 IU/1 ml		168 micrograms
	252 micrograms
336 micrograms
Packs of 4 single pre-filled syringes with PROTECS™ needle guard device		20,000 IU/0.5 ml
	30,000 IU/0.75 ml
40,000 IU/1 ml		168 micrograms
	252 micrograms
336 micrograms
Packs of 6 single pre-filled syringes with PROTECS™ needle guard device
		20,000 IU/0.5 ml
	30,000 IU/0.75 ml
40,000 IU/1 ml	168 micrograms
252 micrograms
336 micrograms

Not all packs may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>See outer carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي إيبريكس على مادة إيبوتين ألفا - البروتين الذي ينشط نخاع العظم لضخ المزيد من خلايا الدم الحمراء والتي تحمل الهيموجلوبين (مادة تنقل الأوكسجين.). إيبوتين ألفا هو نسخة من البروتين البشري إريثروبويتين (إي-ريث-رو-بو-ي-تين) ويعمل بنفس الطريقة.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يستخدم </strong><strong>إيبريكس</strong><strong> لعلاج الأنيميا التي تسببها أمراض الكلى</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند الأطفال في الغسيل الكلوي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند البالغين في الغسيل الكلوي أو الغسيل البريتوني</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند البالغين ممن يعانون من فقر دم شديد لكن حالتهم لم تصل للغسيل البريتوني.</p><p>&nbsp;</p><p>إذا كنت تعاني من مرض كلوي ، فربما يكون لديك نقص في كرات الدم الحمراء إذا كانت الكلية لديك لا تفرز إريثروبويتين (التي لابد منها لإنتاج كرات دم حمراء). ينصح الطبيب بدواء إيبريكس لتنشيط نخاع العظم لإفراز كرات دم حمراء أكثر.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يستخدم </strong><strong>إيبريكس</strong><strong> لعلاج الأنيميا إذا كنت تتلقى العلاج الكيميائي </strong>للأورام الصلبة أو<strong> </strong>الأورام الخبيثة &nbsp;أو أورام الغدد اللمفاوية الخبيثة أو الأورام النخاعية المتعددة (سرطان نخاع العظم) ويقرر طبيبك أنك في حاجة إلى نقل الدم. يمكن لدواء إيبريكس خفض الحاجة إلى نقل الدم.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يستخدم </strong><strong>إيبريكس</strong><strong> في حالات الأنيميا المعتدلة للأشخاص الذين يتبرعون ببعض من دمائهم قبل </strong>العملية الجراحية، لكي يتم ضخها مجدداً لهم أثناء أو بعد العملية. ولأن إيبريكس يقوم بتنشيط كرات الدم الحمراء، يمكن للأطباء أخذ مزيد من الدماء من هؤلاء الأشخاص.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يستخدم </strong><strong>إيبريكس</strong><strong> في حالات الأنيميا المعتدلة للبالغين ممن لديهم عمليات جراحية لتقويم العظام </strong><em>(على سبيل المثال عمليات استبدال الفخذ أو الركبة)</em>، لتقليل الحاجة المحتملة إلى عمليات نقل الدم.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول</strong> <strong>إيبريكس</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من حساسية </strong>ضد إيبوتين ألفا أو أي من مكونات إيبريكس (مدرجة في الفصل 6&nbsp;، <em>محتويات الحزمة و معلومات أخرى</em>).</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا تم تشخيص إصابتك بعدم تنسج الخلايا الحمراء النقي </strong>(لا يمكن لنخاع العظم أن ينتج كرات دم حمراء كافية) بعد استخدام علاج سابق بأي منتج يساعد على تنشيط إنتاج كرات الدم الحمراء (بما في ذلك إيبريكس). قم بالاطلاع على الفصل 4، <em>الآثار الجانبية المحتملة</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من ضغط دم عالي </strong>لا يمكن علاجه بالأدوية بالشكل المناسب.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لتنشيط إنتاج كرات الدم الحمراء (حتى يتمكن الأطباء من أخذ مزيد من الدماء منك<strong>) إذا لم تتمكن من نقل دمك</strong> إليك أثناء أو بعد العملية الجراحية.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك عملية جراحية ضخمة لتقويم العظام </strong>(مثل عملية جراحية في الفخذ أو الركبة)، وكنت:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من أمراض قلبية خطيرة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من اضطرابات خطيرة في الأوردة والشرايين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد أصبت بأزمة قلبية أو سكتة دماغية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكن أن تتناول أدوية لترقيق الدم</p><p>&nbsp;</p><p>فربما يكون إيبريكس غير مناسب لك. برجاء الرجوع إلى طبيبك. بخصوص إيبريكس، بعض الأشخاص يحتاجون إلى أدوية لتقليل مخاطر الإصابة بالجلطات الدموية<strong>. إذا لم تتمكن من تناول الأدوية التي تمنع الجلطات الدموية</strong><strong> </strong><strong>يجب أن لا تتناول </strong><strong>إيبريكس</strong><strong>.</strong></p><p>&nbsp;</p><p><strong>تحذيرات واحتياطات</strong></p><p>&nbsp;</p><p><strong>لابد من توخي الحذر الشديد عند استخدام </strong><strong>إيبريكس</strong></p><p>&nbsp;</p><p><strong>يمكن لدواء </strong><strong>إيبريكس</strong><strong> والأدوية الأخرى التي تستخدم لتنشيط إنتاج كرات الدم الحمراء أن تزيد من مخاطر الإصابة بالجلطات الدموية</strong><strong> </strong><strong>لأي مريض. يمكن أن يتزايد ذلك الخطر إذا كانت لديك عوامل خطر تشير إلى احتمالية الإصابة بالجلطات الدموية</strong><strong> </strong><em>&nbsp;</em><em>(على سبيل المثال، إذا كنت قد أصبت بالجلطة الدموية من قبل أو تعاني من سمنة مفرطة،أو مصاب بمرض السكر أو القلب أو لا تستطيع المشي على قدميك منذ فترة طويلة بسبب جراحة أو مرض). </em>من فضلك قم بإخبار طبيبك عن أي من هذه الأشياء. سيساعدك طبيبك في التوصل إلى قرار ما إذا كان إيبريكس مناسب لك أم لا.</p><p>&nbsp;</p><p><strong>لابد أن تخبر طبيبك</strong> إذا انطبقت عليك أي من الأشياء التالية<strong>. </strong>ربما لا يزال بإمكانك استخدام إيبريكس، لكن قم باستشارة طبيبك أولاً.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعرف أنك تعاني</strong>، أو عانيت، مما يلي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع ضغط الدم؛</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نوبات صرع أو تشنجات</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أمراض الكبد</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أنيميا لأسباب أخرى</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>البرفيرية (اضطراب دم نادر)</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من فشل كلوي مزمن</strong>، ولاسيما إذا كنت لا تستجيب إلى دواء إيبريكس بشكل جيد، فسيقوم طبيبك بالاطلاع على جرعة إيبريكس لأن تكرار جرعة إيبريكس إذا كنت لا تستجيب للعلاج يمكن أن يزيد من مخاطر مرض القلب أو&nbsp; الأوعية الدموية وقد يزيد من مخاطر احتشاء عضلة القلب و السكتات الدماغية وحتى الوفاة.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من مرض السرطان، </strong>فكن على حذر أن بعض الأدوية التي تعمل على تنشيط إنتاج كرات الدم الحمراء<br />(مثل إيبريكس) قد تعمل كعوامل نمو وهو ما قد يؤثر على تطور مرض السرطان، بشكل نظري.<strong> واستناداً إلى وضعك الفردي، فقد يستحسن نقل الدم لك. برجاء استشارة الطبيب في ذلك.</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من مرض السرطان، </strong>فكن على حذر من &nbsp;أن إيبريكس مرتبط بمعدلات بقاء على&nbsp; قيد الحياة أقل و معدلات وفاة أعلى&nbsp; في مرضى سرطان الرأس و العنق و من انتشر لديهم السرطان في الثدي اللذين يتلقون العلاج الكيميائي</p><p>&nbsp;</p><p><strong>توخ الحذر الشديد عند استعمال الأدوية الأخرى التي تنشط إنتاج كرات الدم الحمراء:</strong></p><p>&nbsp;</p><p>إيبريكس هو دواء ضمن مجموعة من الأدوية التي تعمل على تنشيط إنتاج كرات الدم الحمراء كما يفعل بروتين إريثروبويتين البشري. سيقوم طبيب الرعاية الصحية لديك دائماً بتسجيل الدواء الدقيق الذي تتناوله.</p><p>&nbsp;</p><p>إذا تمت كتابة دواء آخر في هذه المجموعة خلافاً لدواء إيبريكس لك أثناء علاجك، فقم باستشارة طبيبك أو الصيدلي لديك قبل استخدامه.</p><p>&nbsp;</p><p><strong>الأدوية الأخرى و </strong><strong>إيبريكس</strong></p><p>&nbsp;</p><p>لا يتفاعل إيبريكس مع أي أدوية أخرى بشكل طبيعي لكن قم باستشارة طبيبك إذا كنت تستخدم (أو استخدمت مؤخراً) أي أدوية أخرى بما في ذلك الأدوية التي حصلت عليها دون توصية من الطبيب.</p><p>&nbsp;</p><p><strong>إذا كنت تتناول عقار </strong><strong>cyclosporin</strong> (يستخدم بعد عمليات زرع الكلى)، فقد يقوم الطبيب بإجراء اختبارات دم لمعرفة مستوى سيكلوسبورين عند تناول إيبريكس.</p><p>&nbsp;</p><p><strong>مكملات الحديد ومحفزات الدم </strong>الأخرى ربما تزيد من فاعلية إيبريكس. سيقرر طبيبك ما إذا كان مناسباً تناول تلك الأدوية أم لا.</p><p>&nbsp;</p><p><strong>إذا قمت بزيارة مستشفى أو عيادة أو طبيب الأسرة</strong>، فقم بإخبارهم أنك تتناول علاج إيبريكس. قد يؤثر على أدوية أخرى أو نتائج تحليلية.</p><p>&nbsp;</p><p><strong>الحمل و الرضاعة</strong></p><p>&nbsp;</p><p><strong>لابد أن تخبر طبيبك</strong> إذا انطبقت عليك أي من الأشياء التالية. ربما لا يزال بإمكانك استخدام إيبريكس، لكن قم باستشارة طبيبك أولاً.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتي امرأة حاملاً</strong>، أو تظنين أنك حامل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتي في مرحلة الرضاعة.</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>قم بتناول هذا الدواء مثلما يخبرك الطبيب بالضبط.</strong> قم باستشارة الطبيب إذا لم تكن متأكداً.</p><p><strong>&nbsp;</strong></p><p><strong>أجرى طبيبك تحليلات الدم</strong> وأوصى بحاجتك إلى إيبريكس.</p><p>&nbsp;</p><p>يمكن تناول إيبريكس عن طريق الحقن:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إما </strong>في الوريد أو أنبوبة تصل إلى الوريد (حقن وريدي)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أو </strong>تحت الجلد (حقن تحت الجلد).</p><p>&nbsp;</p><p>طبيبك هو من سيقرر كيفية حقن إيبريكس. عادة ما يتم الحقن عن طريق الطبيب، أو الممرضة أو أي طبيب من أطباء الرعاية الصحية. بعض الأشخاص، بناء على سبب احتياجهم لعلاج إيبريكس، قد يتعلموا بعد ذلك كيفية حقن أنفسهم بأنفسهم تحت الجلد: انظر <em>الإرشادات الخاصة بكيفية حقن دواء </em><em>إيبريكس</em><em> بنفسك.</em></p><p><em>&nbsp;</em></p><p>لا يجب استخدام إيبريكس:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد انتهاء الصلاحية على الملصق والعلبة الخارجية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف، أو تظن، أنه قد تجمد عن دون قصد، أو</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت مشكلة في الثلاجة.</p><p>&nbsp;</p><p>تتوقف جرعة إيبريكس التي تتناولها على وزنك بالكيلو جرام. سبب مرض الأنيميا هو عامل مهم أيضاً لكي يتمكن طبيبك من تحديد الجرعة الصحيحة.</p><p>&nbsp;</p><p><strong>سيتابع طبيبك ضغط الدم لديك بانتظام </strong>أثناء استخدامك لعقار إيبريكس.</p><p>&nbsp;</p><p><strong>الأشخاص الذين يعانون من أمراض الكلى</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طبيبك هو المسؤول عن الحفاظ على نسبة الهيموجلوبين لديك لتكون بين 10 و 12&nbsp;جرامًا/ديسيلتر لأن نسبة الهيموجلوبين المرتفعة قد تزيد من مخاطر الإصابة بالجلطة الدموية والوفاة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجرعة الأولية المعتادة</strong> من إيبريكس للبالغين والأطفال هي 50 وحدة دولية للكيلو جرام من وزن الجسم ثلاث مرات أسبوعياً.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لمرضى الغسيل البريتوني قد يتم تناول جرعة إيبريكس مرتين أسبوعياَ.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للبالغين والأطفال يتم تناول جرعة إيبريكس عن طريق الحقن سواء في الوريد أو من خلال أنبوبة تمر إلى الوريد. عند عدم توافر الحقن من خلال الوريد أو الأنبوبة، فقد يوصي طبيبك بحقن جرعة إيبريكس تحت الجلد (حقن تحت الجلد). ويشمل ذلك المرضى الذين يخضعون للغسيل أو الذين لم يخضعوا له بعد.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بإجراء تحليلات دم للوقوف على استجابة مرض الأنيميا الذي تعاني منه للجرعة وقد يقوم بتعديل الجرعة، عادة كل أربعة أسابيع.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد معالجة الأنيميا التي تعاني منها، سيواصل طبيبك متابعة الدم لديك بانتظام. قد يتم تعديل جرعة إيبريكس ومدى تكرار تناول الجرعة كذلك للحفاظ على استجابتك للعلاج. سيقوم طبيبك باستخدام أقل جرعة من حيث التأثير للتحكم في أعراض الأنيميا التي تعاني منها.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تستجب بشكل كاف لعقار إيبريكس، فسيقوم طبيبك بالاطلاع على جرعتك وإخبارك إذا كنت في حاجة إلى تغيير جرعات إيبريكس.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الفاصل الزمني بين جرعات إيبريكس طويلاً (أطول من مرة أسبوعياً)، فقد لا تتمكن من الحفاظ على نسبة الهيموجلوبين و قد تكون في حاجة إلى زيادة جرعة إيبريكس أو زيادة مدى تكرار تناول الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات حديد قبل وأثناء العلاج بعقار إيبريكس لجعله أكثر فاعلية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع &nbsp;للغسيل الكلوي عند بدء تناول إيبريكس، فقد يحتاج نظام الغسيل الكلوي الخاص بك للتعديل. سيقرر طبيبك ذلك.</p><p>&nbsp;</p><p><strong>البالغون ممن يخضعون للعلاج الكيميائي</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يوصي طبيبك بعلاج إيبريكس إذا كانت نسبة الهيموجلوبيين لديك 10 جرام/ديسيلتر أو أقل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طبيبك هو المسؤول عن الحفاظ على نسبة الهيموجلوبين لديك لتكون بين 10 و 12&nbsp;جرامًا/ديسيلتر لأن نسبة الهيموجلوبين المرتفعة قد تزيد من مخاطر الإصابة بالجلطة الدموية والوفاة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الأولية <strong>إما</strong> أن تكون 150&nbsp;وحدة دولية لكل كيلو جرام من وزن الجسم ثلاث مرات أسبوعياً أو 450&nbsp;وحدة دولية لكل كيلو جرام من وزن الجسم مرة أسبوعياً.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول جرعة إيبريكس عن طريق الحقن تحت الجلد.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم الطبيب بإجراء تحليلات الدم، وقد يقوم بتعديل الجرعة، بناءً على استجابة حالة الأنيميا لديك لعلاج إيبريكس.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات حديد قبل وأثناء العلاج بعقار إيبريكس لجعله أكثر فاعلية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستواصل تناول علاج إيبريكس لشهر آخر بعد انتهاء العلاج الكيماوي.</p><p>&nbsp;</p><p><strong>تبرع البالغين بدمائهم</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجرعة الاعتيادية</strong> هي 600&nbsp;وحدة دولية لكل كيلو جرام من وزن الجسم مرتين أسبوعياً.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم حقن عقار إيبريكس في الوريد مباشرة بعد تبرعك بالدم لمدة 3 أسابيع قبل العملية الجراحية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات حديد قبل وأثناء العلاج بعقار إيبريكس لجعله أكثر فاعلية.</p><p>&nbsp;</p><p><strong>الجرعات المجدولة للبالغين ممن لديهم عمليات جراحية ضخمة متعلقة بتقويم العظام</strong></p><p><strong><em>&nbsp;</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجرعة التي ينصح بها</strong> هي 600&nbsp;وحدة دولية لكل كيلو جرام من وزن الجسم مرة أسبوعياً.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم حقن عقار إيبريكس تحت الجلد كل أسبوع لمدة ثلاثة أسابيع قبل العملية الجراحية ويوم إجراء العملية.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت هناك حاجة طبية إلى تقليل المدة الزمنية قبل العملية، فسيتم إعطاءك جرعة يومية مقدارها 300 وحدة دولية /كيلو جرام لمدة عشرة أيام قبل العملية، وفي يوم العملية، ولمدة أربعة أيام بعد العملية مباشرة.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا بينت تحاليل الدم أن نسبة الهيموجلوبين مرتفعة جداً قبل العملية، فسيتم إيقاف تناول العقار.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتم إعطاؤك مكملات حديد قبل وأثناء العلاج بعقار إيبريكس لجعله أكثر فاعلية.</p><p>&nbsp;</p><p><strong>الإرشادات الخاصة بكيفية حقن دواء </strong><strong>إيبريكس</strong><strong> بنفسك</strong></p><p><strong>&nbsp;</strong></p><p>عند بدء العلاج، عادة ما يتم حقن عقار إيبريكس عن طريق طاقم طبي أو تمريضي. بعد ذلك، قد يوصي طبيبك بأن تتعلم أنت أو مقدم الرعاية كيف تقوم بحقن عقار إيبريكس تحت الجلد (<em>حقن تحت الجلد</em>) بنفسك.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تحاول أن تقوم بحقن نفسك إلا بعد أن تكون قد تدربت على يد طبيبك أو الممرضة.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دائمًا استخدم عقار </strong><strong>إيبريكس</strong><strong> كما أوصاك طبيبك أو الممرضة بالضبط.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم فقط باستخدام عقار </strong><strong>إيبريكس</strong><strong> إذا تم تخزينه بشكل صحيح - قم بالاطلاع على القسم 5، <em>كيف يتم تخزين </em></strong><strong><em>إيبريكس</em></strong><strong>.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قبل الاستخدام، اترك حقنة </strong><strong>إيبريكس</strong><strong> حتى تصل إلى درجة حرارة الغرفة. ويستغرق ذلك بين 15 و 30 دقيقة. </strong></p><p><em><u>&nbsp;</u></em></p><p><strong>تناول جرعة واحدة فقط من </strong><strong>إيبريكس</strong><strong> من كل سرنجة.</strong></p><p>&nbsp;</p><p>إذا تم حقن إيبريكس تحت الجلد (حقن تحت الجلد)، الكمية التي يتم حقنها لا ينبغي أن تتجاوز واحد ملليلتر في كل سرنجة.</p><p>&nbsp;</p><p>يتم حقن إيبريكس فقط دون خلطه بأي سوائل أخرى للحقن.</p><p>&nbsp;</p><p><strong>لا تقم برج السرنجة التي تحتوي على عقار </strong><strong>إيبريكس</strong><strong>.</strong> يمكن أن يؤدي رج السرنجة بشدة لفترة طويلة إلى إتلاف العقار. إذا تم رج العقار بشدة، فلا تستخدمه.</p><p><strong>&nbsp;</strong></p><p><strong>كيف تحقن نفسك باستخدام حقن مملوءة مسبقاً:</strong></p><p>&nbsp;</p><p>الحقن المملوءة مسبقاً تكون مزودة بجهاز وقاية الإبر <sup>&trade;</sup>PROTECS للحد من إصابات ما بعد الحقن. تتم الإشارة إلى ذلك على العبوة.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202" coordsize="21600,21600"
 o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:315pt;margin-top:28.45pt;width:27pt;height:8.3pt;z-index:251652608;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF
90jcwfIWJU67QAgl6YK0S0CoHGBkTxKLZGx5TGhvj5O2G0SRWNoz/78nu9wcxkFMGNg6quQqL6RA
0s5Y6ir5vt9lD1JwBDIwOMJKHpHlpr69KfdHjyxSmriSfYz+USnWPY7AufNIadK6MEJMx9ApD/oD
OlTrorhX2lFEilmcO2RdNtjC5xDF9pCuTyYBB5bi6bQ4syoJ3g9WQ0ymaiLzg5KdCXlKLjvcW893
SUOqXwnz5DrgnHtJTxOsQfEKIT7DmDSUCaxw7Rqn8787ZsmRM9e2VmPeBN4uqYvTtW7jvijg9N/y
JsXecLq0q+WD6m8AAAD//wMAUEsDBBQABgAIAAAAIQA4/SH/1gAAAJQBAAALAAAAX3JlbHMvLnJl
bHOkkMFqwzAMhu+DvYPRfXGawxijTi+j0GvpHsDYimMaW0Yy2fr2M4PBMnrbUb/Q94l/f/hMi1qR
JVI2sOt6UJgd+ZiDgffL8ekFlFSbvV0oo4EbChzGx4f9GRdb25HMsYhqlCwG5lrLq9biZkxWOiqY
22YiTra2kYMu1l1tQD30/bPm3wwYN0x18gb45AdQl1tp5j/sFB2T0FQ7R0nTNEV3j6o9feQzro1i
OWA14Fm+Q8a1a8+Bvu/d/dMb2JY5uiPbhG/ktn4cqGU/er3pcvwCAAD//wMAUEsDBBQABgAIAAAA
IQDXm/APcwIAANAEAAAOAAAAZHJzL2Uyb0RvYy54bWysVMtu2zAQvBfoPxC8O5JV52EjcqA4cFEg
aAIkRc40RcUCJC5L0pbcov/eIWUlbdpTUR/o5T65s7O6vOrbhu2VdTXpnE9PUs6UllTW+jnnXx7X
kwvOnBe6FA1plfODcvxq+f7dZWcWKqMtNaWyDEm0W3Qm51vvzSJJnNyqVrgTMkrDWJFthcfVPiel
FR2yt02SpelZ0pEtjSWpnIP2ZjDyZcxfVUr6u6pyyrMm53ibj6eN5yacyfJSLJ6tMNtaHp8h/uEV
rag1ir6kuhFesJ2t/0jV1tKSo8qfSGoTqqpaqtgDupmmb7p52AqjYi8Ax5kXmNz/Sys/7+8tq8uc
Z5xp0WJEj6r37Jp6lgV0OuMWcHowcPM91JjyqHdQhqb7yrbhH+0w2IHz4QXbkExC+WGWzVNYJExZ
dnEGGdmT12Bjnf+oqGVByLnF6CKiYn/r/OA6uoRajpq6XNdNEy8Ht2os2wtMGeQoqeOsEc5DmfN1
/B2r/RbW6BCsKaQZKgwaFYkzlBULdAAxeIZe4lC/r07Ps+L8dD45K06nk9k0vZgURZpNbtZFWqSz
9Wo+u/5xLDnGJwHKAbIg+X7TR+DP5yOeGyoPgNnSQFNn5LoGGLfo5F5Y8BL4Ydf8HY6qoS7ndJQ4
25L99jd98AddYOWsA89z7r7uhFUA6JMGkcJSjIIdhc0o6F27IoA6xRYbGUUEWN+MYmWpfcIKFqEK
TEJL1Mq5H8WVH7YNKyxVUUQnUN8If6sfjAypA7RhtI/9k7DmOH8P2D7TuAFi8YYGg+8wvmLnqaoj
RwKwA4rgVrhgbSLLjise9vLXe/R6/RAtfwIAAP//AwBQSwMEFAAGAAgAAAAhAPJpv2vfAAAACQEA
AA8AAABkcnMvZG93bnJldi54bWxMj01PwzAMhu9I/IfISFwQSxhT2bqmE2xwG4d9aOesMW1F41RN
unb/HnOCo+1Xj583W42uERfsQu1Jw9NEgUAqvK2p1HA8fDzOQYRoyJrGE2q4YoBVfnuTmdT6gXZ4
2cdSMIRCajRUMbaplKGo0Jkw8S0S375850zksSul7czAcNfIqVKJdKYm/lCZFtcVFt/73mlINl0/
7Gj9sDm+b81nW05Pb9eT1vd34+sSRMQx/oXhV5/VIWens+/JBtEw41lxl6hhphYgOJDMZ7w4a3hJ
FiDzTP5vkP8AAAD//wMAUEsBAi0AFAAGAAgAAAAhALaDOJL+AAAA4QEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAOP0h/9YAAACUAQAACwAAAAAA
AAAAAAAAAAAvAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA15vwD3MCAADQBAAADgAAAAAA
AAAAAAAAAAAuAgAAZHJzL2Uyb0RvYy54bWxQSwECLQAUAAYACAAAACEA8mm/a98AAAAJAQAADwAA
AAAAAAAAAAAAAADNBAAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAAEAAQA8wAAANkFAAAAAA==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>غطاء الإبرة</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_9"
 o:spid="_x0000_s1033" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:96.4pt;margin-top:27.85pt;width:36pt;height:9pt;
 z-index:251659776;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>الغطاس</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_6"
 o:spid="_x0000_s1030" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:195.2pt;margin-top:28.75pt;width:27pt;height:9pt;
 z-index:251656704;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>العبوة</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_10"
 o:spid="_x0000_s1034" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:124.5pt;margin-top:21.45pt;width:28.8pt;height:18pt;
 z-index:251660800;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>مشابك تنشيط</strong><br /><strong>واقي الإبرة</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_3"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:225pt;margin-top:21.45pt;width:36pt;height:18pt;
 z-index:251653632;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>نافذة العرض</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_4"
 o:spid="_x0000_s1028" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:4in;margin-top:94.45pt;width:36pt;height:9pt;
 z-index:251654656;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>الإبرة<br />&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_5"
 o:spid="_x0000_s1029" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:198pt;margin-top:94.45pt;width:36pt;height:14pt;
 z-index:251655680;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>الملصق<br />&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_7"
 o:spid="_x0000_s1031" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:135pt;margin-top:94.95pt;width:45pt;height:18pt;
 z-index:251657728;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>أجنحة واقي الإبرة<br />&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_8"
 o:spid="_x0000_s1032" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:90pt;margin-top:94.95pt;width:36pt;height:18pt;
 z-index:251658752;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>رأس الغطاس</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_11"
 o:spid="_x0000_s1035" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:70.5pt;margin-top:4.95pt;width:189pt;height:9pt;
 z-index:251661824;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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=
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الشكل 1 يبين شكل الحقن المملوءة مسبقاً.</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:284.5pt;height:100pt;visibility:visible'>
 <v:imagedata src="file:///C:/Users/malqahta/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.emz"
  o:title="" croptop="-41385f" cropbottom="-8193f" cropleft="-3774f"
  cropright="-1f"/>
</v:shape><![endif]--><img width="379" height="133" alt="" src="file:///C:/Users/malqahta/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" />&nbsp;</p><p><img alt="" width="666" height="141" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_12" o:spid="_x0000_s1036"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:198pt;margin-top:1.25pt;width:36pt;height:14pt;z-index:251662848;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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==
" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>الشكل 1</p><p>&nbsp;</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>خذ سرنجة من الثلاجة.</strong> لابد من وصول السائل إلى درجة حرارة الغرفة. لا تقم بإزالة غطاء إبرة السرنجة أثناء ترك الإبرة ليصل المنتج إلى درجة حرارة الغرفة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم بفحص السرنجة </strong>للتأكد من أنها الجرعة الصحيحة، ولم تتجاوز تاريخ صلاحيتها، وليست تالفة. وتأكد من أن السائل شفاف وليس مجمدًا.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم باختيار موضع الحقن. </strong>أفضل موضع للحقن هو أعلى الفخذ وحول البطن لكن بعيداً عن السرة. قم بتغيير موضع الحقن من يوم لآخر.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم بغسل اليدين. استخدم قطنة معقمة على موضع الحقن، </strong>لتعقيمه.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أمسك السرنجة المملوءة من خلال جسم السرنجة مع توجيه إبرة السرنجة المغطاة للأعلى.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تمسك الحقنة من مقدمة الغاطس أو الغاطس أو أجنحة واقي الإبرة أو غطاء الإبرة.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تسحب الغاطس في أي وقت.</strong></p><p>-&nbsp;&nbsp;&nbsp; <strong>لا تقم بإزالة واقي الإبرة من الحقنة الممتلئة مسبقاً حتى تكون جاهزًا لحقن </strong>إيبريكس<strong><sup>&reg;</sup></strong><strong>/</strong><strong>ERYPO<sup>&reg;</sup></strong><strong>.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قم بإزالة غطاء السرنجة</strong> من خلال مسك الأنبوبة وخلع الغطاء بعناية دون ثنيه<strong>. </strong>لا تضغط على الغطاس أو تلمس الإبرة أو تهز السرنجة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تلمس مشابك تنشيط الإبرة (كما يتضح من العلامات النجمية * في الشكل 1) لمنع التغطية المبكرة للإبرة بواقي الإبرة.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اقبض ثنية من الجلد </strong>بين الإبهام والسبابة. لا تضغط عليها.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أدخل الإبرة بأكملها. </strong>قد يبين لك طبيبك أو الممرضة كيفية القيام بذلك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضغط على الغطاس بالإبهام بقدر الإمكان وسوف يؤدي إلى حقن كمية السائل بالكامل. </strong>اضغط عليه ببطء وبالتساوي واستمر في القبض علي ثنية الجلد. <strong>واقي إبرة </strong><strong>PROTECS<sup>&trade;</sup></strong><strong> لن يتم تنشيطه ما لم يتم إعطاء الجرعة كاملة. قد تسمع صوت طقطقة عند تنشيط واقي إبرة </strong><strong>PROTECS<sup>&trade;</sup></strong><strong>.</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عند الضغط على الغطاس إلى نهايته قدر الإمكان، </strong>اسحب الإبرة واترك الجلد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انزع إبهامك من على الغطاس ببطء </strong>لتسمح للسرنجة بالخروج حتى يتم تغطية الإبرة بأكملها بواقي إبرة PROTECS<sup>&trade;</sup>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>عند سحب الإبرة من جلدك، قد يكون هناك نزيف خفيف في مكان الحقن. هذا طبيعي. يمكنك الضغط بمسحة مطهر </strong>على مكان الحقن لبضع ثوان بعد الحقن.</p><p>-&nbsp;&nbsp;&nbsp; <strong>تخلص من السرنجة المستعملة</strong> في حاوية آمنة &ndash;راجع القسم 5، <em>كيفية تخزين </em><em>إيبريكس</em><em>.</em></p><p><em>&nbsp;</em></p><p><strong>إذا استخدمت </strong><strong>إيبريكس</strong><strong> أكثر مما ينبغي</strong></p><p><strong>&nbsp;</strong></p><p>أخبر الطبيب أو الممرضة على الفور إذا كنت تعتقد أنه تم حقنك بكمية كبيرة من إيبريكس. من غير المحتمل وجود آثار جانبية من الجرعات الزائدة من إيبريكس.</p><p>&nbsp;</p><p><strong>إذا كنت قد نسيت أن تستخدم </strong><strong>إيبريكس</strong></p><p>&nbsp;</p><p>استخدم الحقنة التالية بمجرد أن تتذكر. إذا تذكرت قبل يوم من موعد الحقنة التالية، فتجاهل الحقنة الفائتة واستمر حسب جدول مواعيدك الطبيعي.<br />لا تضاعف معدل الحقن.</p><p>&nbsp;</p><p><strong>إذا كنت مريضًا بالتهاب الكبد </strong><strong>C</strong><strong> وتأخذ انترفيرون وريبافيرين</strong></p><p><strong>&nbsp;</strong></p><p>يجب عليك مناقشة هذا الأمر مع طبيبك لأن الجمع بين إيبوتين ألفا مع إنترفيرون وريبافيرين أدى إلى فقدان التأثير وتطور حالة تسمى بعدم تنسج الكريات الحمراء النقي (PRCA)، وهو شكل حاد من فقر الدم، في حالات نادرة. لم تتم الموافقة على إيبريكس لعلاج فقر الدم المرتبط بالتهاب الكبد C.</p><p>&nbsp;</p><p>إذا كان لديك أي أسئلة إضافية عن استخدام هذا المنتج، فاطرحها على طبيبك أو الممرضة أو الصيدلي.</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، إيبريكس<strong> </strong>يمكن أن يسبب آثارًا جانبية على الرغم من أن الجميع لا يصاب بها.</p><p>&nbsp;</p><p><strong>أخبر طبيبك أو الممرضة على الفور</strong> إذا لاحظت أية أعراض من تلك الواردة في هذه القائمة.</p><p>&nbsp;</p><p><u>الأعراض الجانبية الشائعة جدًا</u></p><p>يمكن أن تؤثر على أكثر من 1 من بين كل 10 أشخاص يستخدمون إيبريكس.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الإسهال</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الشعور بالغثيان في معدتك</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>القيء</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الحمى</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>احتقان الجهاز التنفسي، </strong>مثل انسداد الأنف واحتقان الحلق، وقد تم الإبلاغ عن ذلك في المرضى الذين يعانون من أمراض الكلى والذين لا يخضعون للديلزة بعد.</p><p><u>&nbsp;</u></p><p><u>الأعراض الجانبية الشائعة</u></p><p>قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص يستخدمون إيبريكس.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع ضغط الدم. الصداع</strong>، وبالأخص الصداع المفاجئ الذي يشبه الصداع النصفي والذي يشبه الطعن في الرأس، <strong>الشعور بالتشوش أو وجود نوبات</strong> قد تكون علامات على الارتفاع المفاجئ في ضغط الدم. وهذا يتطلب علاجًا عاجلاً. قد يتطلب ارتفاع ضغط الدم العلاج بالعقاقير (أو تعديل أي أدوية تأخذها بالفعل لارتفاع ضغط الدم).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجلطات الدموية </strong>(بما في ذلك خثار الأوردة العميقة والانسداد) والتي قد تتطلب علاجًا عاجلاً. قد تعاني من <strong>ألم في الصدر أو انقطاع النفس، أو تورم مؤلم واحمرار وعادةً يكون في الساق</strong> كأعراض.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السعال</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الطفح الجلدي والذي قد ينتج من حساسية.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>آلام العظام أو العضلات</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أعراض تشبه الأنفلونزا</strong>، مثل الصداع وأوجاع وآلام في المفاصل والشعور بالضعف والقشعريرة والتعب والدوخة. قد تكون هذه الأعراض أكثر شيوعًا في بداية العلاج. إذا كنت تعاني من هذه الأعراض أثناء الحقن في الوريد، فإن الحقن بشكل بطيء يمكن أن يساعد على تجنبها في المستقبل.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>احمرار وحرقان وألم في مكان الحقن</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تورم الكاحلين أو القدمين أو الأصابع</strong></p><p>&nbsp;</p><p><u>الأعراض الجانبية غير الشائعة</u></p><p>قد تؤثر على ما يصل إلى 1 من كل 100 شخص يستخدمون إيبريكس.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>النسب العالية للبوتاسيوم في الدم</strong> والتي يمكن أن تسبب ضربات قلب غير طبيعية (وهذا هو أحد الآثار الجانبية الشائعة للغاية لدى مرضى الغسيل ).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>النوبات</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>احتقان الأنف أو المجرى الهوائي</strong></p><p>&nbsp;</p><p><u>الأعراض الجانبية النادرة جدًا</u></p><p>قد تؤثر على ما يصل إلى 1 من كل 10,000 شخص يستخدمون إيبريكس.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أعراض عدم تنسج الكريات الحمراء النقي (</strong><strong>PRCA</strong><strong>)</strong></p><p>&nbsp;</p><p><strong>عدم تنسج الكريات الحمراء النقي </strong>يعني أن النخاع العظمي لا يصنع ما يكفي من خلايا الدم الحمراء. يسبب <strong>عدم تنسج الكريات الحمراء النقي فقر الدم المفاجئ والحاد. الأعراض هي:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تعب غير طبيعي،</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الشعور بالدوخة،</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انقطاع النفس.</strong></p><p>&nbsp;</p><p>ومن النادر جدًا ما تم الإبلاغ عن ظهور <strong>عدم تنسج الكريات الحمراء النقي، </strong>وقد ظهر في أغلب الحالات لدى المرضى الذين يعانون من أمراض الكلى بعد شهور إلى سنوات من العلاج بـإيبريكس وغيره من المنتجات التي تحفز إنتاج خلايا الدم الحمراء.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث زيادة في مستويات خلايا الدم الصغيرة (وتسمى الصفائح الدموية)، التي تشارك عادة في تكوين جلطة دموية، وخاصةً عند بدء العلاج. سوف يتحقق طبيبك من ذلك.</p><p>&nbsp;</p><p>إذا كنت تتلقى غسيل كلوي :</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد تتكون الجلطات الدموية </strong>(التخثر) في تحويلة الغسيل الكلوي . ويحتمل ذلك أكثر إذا كان لديك انخفاض في ضغط الدم أو إذا كان الناسور به مضاعفات.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجلطات الدموية</strong> قد تتكون أيضًا في نظام الغسيل الكلوي &nbsp;الخاص بك. قد يقرر طبيبك زيادة جرعة الهيبارين أثناء الغسيل الكلوي .</p><p><strong>&nbsp;</strong></p><p><strong>أخبر طبيبك أو الممرضة<em> </em>على الفور</strong> إذا كنت على دراية بأحد تلك الأعراض أو إذا لاحظت أية أعراض أخرى أثناء تلقيك علاج إيبريكس<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><u>الإبلاغ عن الآثار الجانبية </u></p><p>إذا واجهت أي آثار جانبية، فتحدث مع طبيبك أو الممرضة أو الصيدلي. يشمل ذلك أي آثار جانبية ممكنة لم يتم سردها في هذه النشرة.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يحفظ الدواء بعيدًا عن متناول ومرأى الأطفال.</strong></p><p>&nbsp;</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية، والمدون على العلبة وعلى الملصق بعد حروف EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p>&nbsp;</p><p>يخزن في الثلاجة (من 2&deg; درجة مئويةإلى 8&deg; درجة مئوية). )36 درجة فهرنهايت إلى 46 درجة فهرنهايت) بعيدا عن حجرة التجميد،</p><p>المحاقن إيبريكس التي يتم استخدامها أو على وشك أن يتم استخدامها يمكن الاحتفاظ بها في درجة حرارة الغرفة</p><p>(وليس أعلى من 25 &ordm; درجة مئوية) لفترة قصوى 7 أيام.</p><p>&nbsp;</p><p>لا ترج العبوة أو تجمدها.</p><p>&nbsp;</p><p>خزن الدواء في العبوة الأصلية لحمايته من الضوء.</p><p>لا تستخدم هذا الدواء إذا لاحظت أن ختم الإغلاق مفتوحًا أو إذا تغير لون السائل أو إذا كان بإمكانك أن ترى جزيئات تطفو بداخله. في حالة ملاحظة حدوث أي من هذه الأمور، فتخلص من المنتج الدوائي.</p><p>&nbsp;</p><p><strong>لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو المخلفات المنزلية.</strong> اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة لاستخدامها. سوف تساعد هذه التدابير على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>نص نشرة معلومات المريض</p><p><strong>المادة الفعالة هي:</strong> إيبوتين ألفا (لمعرفة الكمية انظر الجدول أدناه).</p><p><strong>المكونات الأخرى هي:</strong>&nbsp; بوليسوربات 80 وكلوريد الصوديوم وثنائي هيدرات فوسفات ثنائي هيدروجين الصوديوم وثنائي هيدرات فوسفات ثنائي الصوديوم والجلايسين وماء للحقن.</p><p>&nbsp;</p><p>هذا المنتج الدوائي يحتوي على أقل من 1 ملليمول صوديوم (23 ميلليجرام)، لكل جرعة، أي أن المنتج يمكن أن يعد &quot;خاليًا من الصوديوم.&quot;</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يُقدَم إيبريكس كمحلول للحقن في محقنة معبأة مسبقًا. الحقن المعبأة مسبقاً تكون مزودة بجهاز وقاية الإبر &trade;PROTECS (انظر الجدول أدناه). إيبريكس هو محلول صافٍ وعديم اللون. العرض العروض المتطابقة في الكمية / الحجم لكل تركيز مقدار إيبوتين ألفا عبوات 6 سرنجات فردية معبأة مسبقًا ومزودة بجهاز واقي الإبر &trade;PROTECS 2,000 وحدة دولية/مل: 1,000 وحدة دولية/0.5 مل 4,000 وحدة دولية/مل: 2,000 وحدة دولية/0.5 مل 10,000 وحدة دولية/مل: 3,000 وحدة دولية/0.3 مل 4,000 وحدة دولية/0.4 مل 5,000 وحدة دولية/0.5 مل 6,000 وحدة دولية/0.6 مل 8,000 وحدة دولية/0.8 مل 10,000 وحدة دولية/1 مل 8.4 ميكروجرام 16.8 ميكروجرام 25.2 ميكروجرام 33.6 ميكروجرام 42.0 ميكروجرام 50.4 ميكروجرام 67.2 ميكروجرام 84.0 ميكروجرام عبوات 1 سرنجة مفردة معبأة مسبقًا ومزودة بجهاز واقي الإبر &trade;PROTECS 20,000 وحدة دولية/0.5 مل 30,000 وحدة دولية/0.75 مل 40,000 وحدة دولية/1 مل 168 ميكروجرام 252 ميكروجرام 336 ميكروجرام عبوات 4 سرنجات مفردة معبأة مسبقًا ومزودة بجهاز واقي الإبر &trade;PROTECS 20,000 وحدة دولية/0.5 مل 30,000 وحدة دولية/0.75 مل 40,000 وحدة دولية/1 مل 168 ميكروجرام 252 ميكروجرام 336 ميكروجرام عبوات 6 سرنجات فردية معبأة مسبقًا ومزودة بجهاز واقي الإبر &trade;PROTECS 20,000 وحدة دولية/0.5 مل 30,000 وحدة دولية/0.75 مل 40,000 وحدة دولية/1 مل 168 ميكروجرام 252 ميكروجرام 336 ميكروجرام قد لا تكون جميع العبوات متوفرة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>انظر العبوة الخارجية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل  2016.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EPREX, ERYPO 2,000 IU/mL solution for injection in pre-filled syringe.
EPREX, ERYPO 4,000 IU/mL solution for injection in pre-filled syringe.
EPREX, ERYPO 10,000 IU/mL solution for injection in pre-filled syringe.
EPREX, ERYPO 40,000 IU/mL solution for injection in pre-filled syringe.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EPREX, ERYPO 2,000 IU/mL solution for injection in pre-filled syringe
Epoetin alfa 2,000 IU/mL (16.8 micrograms per mL), produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology

A pre-filled syringe of 0.5 mL contains 1,000 IU (8.4 micrograms) of epoetin alfa.

EPREX, ERYPO 4,000 IU/mL solution for injection in pre-filled syringe
Epoetin alfa 4,000 IU/mL (33.6 micrograms per mL), produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology

A pre-filled syringe of 0.5 mL contains 2,000 IU (16.8 micrograms) of epoetin alfa.

EPREX, ERYPO 10,000 IU/mL solution for injection in pre-filled syringe
Epoetin alfa 10,000 IU/mL (84.0 micrograms per mL), produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology

A pre-filled syringe of 0.3 mL contains 3,000 IU (25.2 micrograms) of epoetin alfa
A pre-filled syringe of 0.4 mL contains 4,000 IU (33.6 micrograms) of epoetin alfa
A pre-filled syringe of 0.5 mL contains 5,000 IU (42.0 micrograms) of epoetin alfa
A pre-filled syringe of 0.6 mL contains 6,000 IU (50.4 micrograms) of epoetin alfa
A pre-filled syringe of 0.8 mL contains 8,000 IU (67.2 micrograms) of epoetin alfa
A pre-filled syringe of 1.0 mL contains 10,000 IU (84.0 micrograms) of epoetin alfa

EPREX, ERYPO 40,000 IU/mL solution for injection in pre-filled syringe
Epoetin alfa 40,000 IU/mL (336.0 micrograms per mL), produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology

A pre-filled syringe of 0.5 mL contains 20,000 IU (168.0 micrograms) of epoetin alfa
A pre-filled syringe of 0.75 mL contains 30,000 IU (252.0 micrograms) of epoetin alfa
A pre-filled syringe of 1.0 mL contains 40,000 IU (336.0 micrograms) of epoetin alfa

Excipient(s) with known effect
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium free.”

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection in pre-filled syringe.

Clear, colourless solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EPREX, ERYPO is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults and paediatrics aged 1 to 18&nbsp;years on haemodialysis and adult patients on peritoneal dialysis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in adults with renal insufficiency not yet undergoing dialysis for the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients.</p><p>&nbsp;</p><p>EPREX, ERYPO is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient&rsquo;s general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.</p><p>&nbsp;</p><p>EPREX, ERYPO is indicated in adults in a predonation programme to increase the yield of autologous blood. Treatment should only be given to patients with moderate anaemia (haemoglobin concentration range between 10 to 13&nbsp;g/dL [6.2 to 8.1&nbsp;mmol/L], no iron deficiency) if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).</p><p><strong><em>&nbsp;</em></strong></p><p>EPREX, ERYPO is indicated for non-iron deficient adults prior to major elective orthopaedic surgery having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13&nbsp;g/dL) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1,800&nbsp;mL).</p><p>&nbsp;</p><p>EPREX, ERYPO is indicated for the treatment of symptomatic anaemia (haemoglobin concentration of &le;10&nbsp;g/dL) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin (&lt;200&nbsp;mU/mL).</p><p><strong><em>&nbsp;</em></strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p>All other causes of anaemia (iron, folate or Vitamin B<sub>12</sub> deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be evaluated and treated prior to initiating therapy with epoetin alfa, and when deciding to increase the dose. In order to ensure optimum response to epoetin alfa, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section&nbsp;4.4).</p><p>&nbsp;</p><p><strong><em>Treatment of symptomatic anaemia in adult chronic renal failure patients</em></strong></p><p>&nbsp;</p><p>Anaemia symptoms and sequelae may vary with age, gender, and co-morbid medical conditions; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p>The recommended desired haemoglobin concentration range is between 10&nbsp;g/dL to 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L). EPREX, ERYPO should be administered in order to increase haemoglobin to not greater than 12&nbsp;g/dL (7.5&nbsp;mmol/L). A rise in haemoglobin of greater than 2&nbsp;g/dL (1.25&nbsp;mmol/L) over a four week period should be avoided. If it occurs, appropriate dose adjustment should be made as provided.</p><p>&nbsp;</p><p>Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin concentration range may be observed. Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin concentration range of 10&nbsp;g/dL (6.2&nbsp;mmol/L) to 12&nbsp;g/dL (7.5&nbsp;mmol/L).</p><p>&nbsp;</p><p>A sustained haemoglobin level of greater than 12&nbsp;g/dL (7.5&nbsp;mmol/L) should be avoided. If the haemoglobin is rising by more than 2&nbsp;g/dL (1.25&nbsp;mmol/L) per month, or if the sustained haemoglobin exceeds 12&nbsp;g/dL (7.5&nbsp;mmol/L) reduce the EPREX, ERYPO dose by 25%. If the haemoglobin exceeds 13&nbsp;g/dL (8.1&nbsp;mmol/L), discontinue therapy until it falls below 12&nbsp;g/dL (7.5&nbsp;mmol/L) and then reinstitute EPREX, ERYPO therapy at a dose 25% below the previous dose.</p><p>&nbsp;</p><p>Patients should be monitored closely to ensure that the lowest approved effective dose of EPREX, ERYPO is used to provide adequate control of anaemia and of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12&nbsp;g/dL (7.5&nbsp;mmol/L).</p><p>Caution should be exercised with escalation of ESA doses in patients with chronic renal failure. In patients with a poor haemoglobin response to ESA, alternative explanations for the poor response should be considered (see section 4.4 and 5.1).</p><p>&nbsp;</p><p>Treatment with EPREX, ERYPO is divided into two stages &ndash; correction and maintenance phase.</p><p><strong>&nbsp;</strong></p><p><strong><em>Adult haemodialysis patients</em></strong></p><p>&nbsp;</p><p>In patients on haemodialysis where intravenous access is readily available, administration by the intravenous route is preferable.</p><p>&nbsp;</p><p><em><u>Correction phase</u></em></p><p>&nbsp;</p><p>The starting dose is 50&nbsp;IU/kg, 3&nbsp;times per week.</p><p>&nbsp;</p><p>If necessary, increase or decrease the dose by 25&nbsp;IU/kg (3&nbsp;times per week) until the desired haemoglobin concentration range between 10&nbsp;g/dL to 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L) is achieved (this should be done in steps of at least four&nbsp;weeks).</p><p>&nbsp;</p><p><em><u>Maintenance phase</u></em></p><p>&nbsp;</p><p>The recommended total weekly dose is between 75&nbsp;IU/kg and 300&nbsp;IU/kg.</p><p>&nbsp;</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin values within the desired concentration range between 10&nbsp;g/dL to 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L).</p><p><strong>&nbsp;</strong></p><p>Patients with very low initial haemoglobin (&lt;&nbsp;6&nbsp;g/dL or &lt;&nbsp;3.75&nbsp;mmol/L)<sup> </sup>may require higher maintenance doses than patients whose initial anaemia is less severe (&gt;&nbsp;8&nbsp;g/dL or &gt;&nbsp;5&nbsp;mmol/L).</p><p>&nbsp;</p><p><strong><em>Adult patients with renal insufficiency not yet undergoing dialysis</em></strong></p><p>&nbsp;</p><p>Where intravenous access is not readily available EPREX, ERYPO may be administered subcutaneously.</p><p>&nbsp;</p><p><em><u>Correction phase</u></em></p><p>&nbsp;</p><p>Starting dose of 50&nbsp;IU/kg, 3&nbsp;times per week, followed if necessary by a dosage increase with 25&nbsp;IU/kg increments (3&nbsp;times per week) until the desired goal is achieved (this should be done in steps of at least four&nbsp;weeks).</p><p>&nbsp;</p><p><em><u>Maintenance phase</u></em></p><p>&nbsp;</p><p>During the maintenance phase, EPREX, ERYPO can be administered either 3&nbsp;times per week, and in the case of subcutaneous administration, once weekly or once every 2&nbsp;weeks.</p><p>&nbsp;</p><p>Appropriate adjustment of dose and dose intervals should be made in order to maintain haemoglobin values at the desired level: haemoglobin between 10&nbsp;g/dL and 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L). Extending dose intervals may require an increase in dose.</p><p>&nbsp;</p><p>The maximum dosage should not exceed 150&nbsp;IU/kg 3&nbsp;times per week, 240&nbsp;IU/kg (up to a maximum of 20,000&nbsp;IU) once weekly, or 480&nbsp;IU/kg (up to a maximum of 40,000&nbsp;IU) once every 2&nbsp;weeks.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Adult peritoneal dialysis patients</em></strong></p><p>&nbsp;</p><p>Where intravenous access is not readily available EPREX, ERYPO may be administered subcutaneously.</p><p>&nbsp;</p><p><em><u>Correction phase</u></em></p><p>&nbsp;</p><p>The starting dose is 50&nbsp;IU/kg, 2&nbsp;times per week.</p><p>&nbsp;</p><p><em><u>Maintenance phase</u></em></p><p><em><u>&nbsp;</u></em></p><p>The recommended maintenance dose is between 25&nbsp;IU/kg and 50&nbsp;IU/kg, 2&nbsp;times per week in 2 equal injections.</p><p>&nbsp;</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin values at the desired level between 10&nbsp;g/dL to 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L).</p><p>&nbsp;</p><p><strong><em>Treatment of adult patients with chemotherapy-induced anaemia</em></strong></p><p>&nbsp;</p><p>Anaemia symptoms and sequelae may vary with age, gender, and overall burden of disease; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p>EPREX, ERYPO should be administered to patients with anaemia (e.g. haemoglobin concentration &le;&nbsp;10&nbsp;g/dL (6.2&nbsp;mmol/L)).</p><p>&nbsp;</p><p>The initial dose is 150&nbsp;IU/kg subcutaneously, 3&nbsp;times per week.</p><p>&nbsp;</p><p>Alternatively, EPREX, ERYPO can be administered at an initial dose of 450&nbsp;IU/kg subcutaneously once weekly.</p><p>&nbsp;</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin concentrations within the desired concentration range between 10&nbsp;g/dL to 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L).</p><p>&nbsp;</p><p>Due to intra-patient variability, occasional individual haemoglobin concentrations for a patient above and below the desired haemoglobin concentration range may be observed. Haemoglobin variability should be addressed through dose management, with consideration for the desired haemoglobin concentration range between 10&nbsp;g/dL (6.2&nbsp;mmol/L) to 12&nbsp;g/dL (7.5&nbsp;mmol/L). A sustained haemoglobin concentration of greater than 12&nbsp;g/dL (7.5&nbsp;mmol/L) should be avoided; guidance for appropriate dose adjustment for when haemoglobin concentrations exceed 12&nbsp;g/dL (7.5&nbsp;mmol/L) are described below.</p><p>&nbsp;</p><p>If the haemoglobin concentration has increased by at least 1&nbsp;g/dL (0.62&nbsp;mmol/L) or the reticulocyte count has increased &ge;&nbsp;40,000&nbsp;cells/mL above baseline after 4&nbsp;weeks of treatment, the dose should remain at 150&nbsp;IU/kg 3&nbsp;times per week or 450&nbsp;IU/kg once weekly.</p><p>&nbsp;</p><p>If the haemoglobin concentration increase is &lt;&nbsp;1&nbsp;g/dL (&lt;&nbsp;0.62&nbsp;mmol/L) and the reticulocyte count has increased &lt;&nbsp;40,000&nbsp;cells/mL above baseline, increase the dose to 300&nbsp;IU/kg 3&nbsp;times per week. If after an additional 4&nbsp;weeks of therapy at 300&nbsp;IU/kg 3&nbsp;times per week, the haemoglobin concentration has increased &ge;&nbsp;1&nbsp;g/dL (&ge;&nbsp;0.62&nbsp;mmol/L) or the reticulocyte count has increased &ge;&nbsp;40,000&nbsp;cells/mL, the dose should remain at 300&nbsp;IU/kg 3&nbsp;times per week.</p><p>&nbsp;</p><p>If the haemoglobin concentration has increased &lt;&nbsp;1&nbsp;g/dL (&lt;&nbsp;0.62&nbsp;mmol/L) and the reticulocyte count has increased &lt;&nbsp;40,000&nbsp;cells/mL above baseline, response is unlikely and treatment should be discontinued.</p><p>&nbsp;</p><p><strong><em>Dose adjustment to maintain haemoglobin concentrations between 10&nbsp;g/dL to 12&nbsp;g/dL</em></strong></p><p><em>&nbsp;</em></p><p>If the haemoglobin concentration is increasing by more than 2&nbsp;g/dL (1.25&nbsp;mmol/L) per month, or if the haemoglobin concentration level exceeds 12&nbsp;g/dL (7.5&nbsp;mmol/L), reduce the EPREX, ERYPO dose by about 25 to 50%.</p><p>&nbsp;</p><p>If the haemoglobin concentration level exceeds 13&nbsp;g/dL (8.1&nbsp;mmol/L), discontinue therapy until it falls below 12&nbsp;g/dL (7.5&nbsp;mmol/L) and then reinitiate EPREX, ERYPO therapy at a dose 25% below the previous dose.</p><p><br /><img alt="" width="912" height="571" src="data:image/png;base64,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" /></p><p>Patients should be monitored closely to ensure that the lowest approved dose of erythropoiesis-stimulating agent (ESA) is used to provide adequate control of the symptoms of anaemia.</p><p><em><u>&nbsp;</u></em></p><p>EPREX, ERYPO therapy should continue until one month after the end of chemotherapy.</p><p>&nbsp;</p><p><strong><em>Treatment of adult surgery patients in an autologous predonation programme</em></strong></p><p>&nbsp;</p><p>Mildly anaemic patients (haematocrit of 33 to 39%) requiring predeposit of &ge;&nbsp;4&nbsp;units of blood should be treated with EPREX, ERYPO 600&nbsp;IU/kg intravenously, 2&nbsp;times per week for 3&nbsp;weeks prior to surgery. EPREX, ERYPO should be administered after the completion of the blood donation procedure.</p><p>&nbsp;</p><p><strong><em>Treatment of adult patients scheduled for major elective orthopaedic surgery</em></strong></p><p>&nbsp;</p><p>The recommended dose is EPREX, ERYPO 600&nbsp;IU/kg administered subcutaneously weekly for three weeks (days -21, -14 and -7) prior to surgery and on the day of surgery.</p><p>&nbsp;</p><p>In cases where there is a medical need to shorten the lead time before surgery to less than three weeks, EPREX, ERYPO 300&nbsp;IU/kg should be administered subcutaneously daily for 10 consecutive days prior to surgery, on the day of surgery and for four days immediately thereafter.</p><p>&nbsp;</p><p>If the haemoglobin level reaches 15&nbsp;g/dL, or higher, during the preoperative period, administration of EPREX, ERYPO should be stopped and further dosages should not be administered.</p><p>&nbsp;</p><p><strong><em>Treatment of adult patients</em></strong> <strong><em>with low- or intermediate-1-risk MDS</em></strong></p><p>&nbsp;</p><p>EPREX, ERYPO should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration &le;10&nbsp;g/dL (6.2&nbsp;mmol/L)).</p><p>&nbsp;</p><p>The recommended starting dose is EPREX, ERYPO 450&nbsp;IU/kg (maximum total dose is 40,000&nbsp;IU) administered subcutaneously once every week, with not less than 5&nbsp;days between doses.</p><p>&nbsp;</p><p>Appropriate dose adjustments should be made to maintain haemoglobin concentrations within the target range of 10&nbsp;g/dL to 12&nbsp;g/dL (6.2 to 7.5&nbsp;mmol/L). It is recommended that initial erythroid response be assessed 8 to 12&nbsp;weeks following initiation of treatment.&nbsp; Dose increases and decreases should be done one dosing step at a time (see diagram below). A haemoglobin concentration of greater than 12&nbsp;g/dL (7.5&nbsp;mmol/L) should be avoided.</p><p>&nbsp;</p><p><em><u>Dose increase:</u></em> Dose should not be increased over the maximum of 1050&nbsp;IU/kg (total dose 80,000&nbsp;IU) per week. If the patient loses response or haemoglobin concentration drops by &ge;1&nbsp;g/dL upon dose reduction the dose should be increased by one dosing step. A minimum of 4&nbsp;weeks should elapse between dose increases.</p><p>&nbsp;</p><p><em><u>Dose hold and decrease:</u> </em>Epoetin alfa should be withheld when the haemoglobin concentration exceeds 12&nbsp;g/dL (7.5&nbsp;mmol/L). Once the haemoglobin level is &lt;11&nbsp;g/dL the dose can be restarted on the same dosing step or one dosing step down based on physician judgement. Decreasing the dose by one dosing step should be considered if there is a rapid increase in haemoglobin (&gt;&nbsp;2&nbsp;g/dL over 4&nbsp;weeks).</p><p><br /><img alt="" width="499" height="190" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAfMAAAC+CAYAAAAhvuZNAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAAEnQAABJ0Ad5mH3gAAB4FSURBVHhe7Z1NyCRX9YeTd4wm0RA1g0Q0IOoiILgS16KgYraCC0EIuJHJrCIuXAjKYJAMiBpRVAgxign4AUJQR3FAcSuiC1F0BEFwoSaK4EK05en0mf/J/Vf121X3/bh163ng0NW36lZ39a17fvfcj+pbNiIiIrJoFHMREZGFo5iLiIgsHMVcRERk4SjmIiIiC0cxFxERWTiKuYiIyMJRzEVERBaOYi4iIrJwFHMREZGF06SYf+pTn9pa8NGPfnRzyy23bN7whjdsfvGLX+xSRUREBJoUc4Q7xJzXEPL3ve99m7e85S3bdBEREXmeZsX8L3/5y+b3v//9dvsVr3jFdjv2zeHSpUvbvJ/5zGd2KSIi0go3btzY3H777Zvnnntul3I473rXu3Zb+zn0uCXSrJg/88wz2yic7YjS6WKny30OH/zgBzcvetGLFHMR2YJv0ert8uXLu1+0Ds5zxx13bK5cubJLORy+B5rx05/+dNTYz3G90uSVxRg5lltSdLN/8Ytf3L2bhmIuIpnwMXL+/P3vf9/cdttt2/K4++67N//97393ew4jyvIQ65Vmr4wonNZUJlpYc1DMRSTTu3NfEo888sjmla985bY8EPXPfvazuz2HEWV5iPVKs1fGGDnd60TmRORsx7j5HBRzEcn07tyXxMWLF18guPfee+9uz2GQhx5ddGKf9VzeTV4ZYxtMesuFi5HGvjko5iKSCb8i58uXvvSl/yfmjJ0/8cQTuyOO59By7Lm8m7wylqHxozMBjsg8jDT2zUExF5EM/qRn574UXve6190si2xvfOMbd0ccD8cf13PL0C3H9UqTV8YPPvRwmJrCUMxFJIMv6dm5L4FvfvObm3vuuedmWdx11103t++8887Nd77znd2R+4nhWJY0D0F6BIe90uSdzI8+JuZlYRxaOIj50dGRYi4iW0I0ThtERoZ5/etff7McMGayx6x27K1vfevuyP2wyonjGYotx84/9KEP3Ry25X2vNCvm/PgIdTbSctc72xTQITA78r3vfe/mRz/60S5FRNZMCMY+WD2DrylFgEiPdPKXj5mO9DD8VLAvX4b0EKBvfOMbW2ObtMiDSMV5SiLwiXxzVwGdNg8++ODWL2Nve9vbNm9+85u3r5H2/ve/f3fkfvhdY3h2zNg/Frn3QJNiPlQQ+0xEZCrH+Q8EHDFEjEsxR0gj4iYSzIKKiI6J5758JXwm5wrYLr8H33/os/gcvjvs+z49QQMmArzSSB9rOPVCs2LOj89NuM+i4A7lj3/8425LRNZOOPrjwNeUIkqEHAJJtMd5Qiw4fkw89+UrmSvmEaVGFLrv+7TEr3/96+0Mdl5rYMUTv1PY3BVQS6NJMS9v2H0ceizPZr9w4YJj5iKyZa6YI75lviyqRN7R5ctriPVx+Ur4zDliTkROZB5kMef7YCFw9A5Ed37YeQn/xz72se14+Uc+8pFdynSY0c73x2qeS7JEmhTzzFirdSrOZheRTIjXcZQiilCU+cZEkHyIJUzJB3PFPIs3xHvEDZGPiD0aF6STRk9ndM2fB4g532eOmPP9aZiQPxtpa6FJMS8LJiAtbsSpKOYikin9yxiliIYIZl/E+zFRjn1T880Rc4SZyDtDPoQ6T56DITGf+98XJ0GNmA8JedhaBL1JMS8LJuCGm7vMQzEXkUzpX8Y4TkTxS7wf69bNx07Jd6iYZ4HGd5aCTD7SyYtgZ/CnnANjOzc0zpoaMaehUl4310Ja9Iz0TpNinm9QtgNu+vx+Coq5iGTwJYf4EwSwFFGELwILBCOLLuIRAk2+HCnvy1dSijnHc644N13ipVDl/QHniDFyPjsiVY6L79ICNWJOvqGGSDSY1kCTV5lbWVFI3LjcqHMLRjEXkQy+ZJ8/wecg5HEcohhBBkLIe9I5JkfHCORQHtiXL0M6fpDjYhwbP8iYd5y7zI9gl+JMXo4N0cev8p7vwHeJzwg7zy7pGjHnt0AfaABlI41rXQNNijmFkG+wbHmW5hQUcxHJhE/phby2/BAQ/yze5x3F1og5QxdRntlorIw1mHqj2TuZm6wsGFpYQ10ph6CYi0gm/EoP4Bcj+j4UgqYcySOIU89xktSIOSDaNGjQCYzttQg5NH0nc4Nyg2HlONBUEHPXmYtI0JOY030+tYscoctDAvu6/c8CxBwfPVfM106TdzItxiFqbrTr169vn8/+q1/9apciImumJzHvgRs3bmyeeuqp7etUIujL8N7I/JwZq2CMB53nBA0R6QfFvB/omchDBnSzR/muRTOauZPzWAcFENvZ6AaaW/l+97vfbf8b989//vMuRUTWTDh7aYNr165trly5sn2dCoIdUXhMoEYvmOS3ljJu6ir3zWIPY6nBHBgz57m/jpmLCIRPkTZgzPzo6Gj2OnPIy+3YPu8Z+mdJc1cZ6yKHIvOa2YnOZheRDH5mLY5+CdSuM6ebPZ5FEvOuIkBcA01eZTww5iRRzEUko5i3RY2YE+SFkOcxcsQ8hL13mr+TidSJyml11cxMVMxFJKOYt0XtOvO108ydTGuKgmS8I1pWkRZW8zQfxVxEMuFXpA1OQswZJ49lanMfMLZUmrmTEWnGPaIAKJSobKRTOIyZ5+UHU1DMRSSjmLdFjZijG/TgRpmG5S733mnmTqYg8qJ/hJvCIBoPga+ZmaiYi0gmHL60QY2Yh14MmWPmZww/ehCijVFImXzcFBRzEcmEj5E2qBFz8jEBjjlWOehjMvV5Pm/+LGnmTuYHj8g8j5XnZ7LzAIBS3A8FMXeduYgE4WOkDRDzmnXmWSuiXBm+XUsZN3OVCDiCHk95w/J4B60tWl65wKbwj3/8Y/Ozn/1s85///GeXIiJrJvyMtMNzzz2325oGc6liOBaibEsd6Zlm7mQKggIZKoDoKiF9LeMfInK6hK+R5YN+ZM3IOpJFvmcWcSfHUoOwOXz+85/fPPjgg9t/TxMRUczb4vHHH9+8+93v3r7WUvNMkqWymjuZMXPGYxwzFxFQzNviJNaZr5lVibmz2UUkUMzbQjGvQzEXkVWimLeFYl7Hou5kJjLwcJk5KOYiklHM26JGzA+dGN3zBOom72QW/sfs9SGbg2IuIpkafyInT42Yk++4WevxiPBeafLK9gk5NgfFXEQyNf5ETp5aMT/UeqVZMWdtebkkjYh9bmEo5iKS6d25Lw3FvI4mr4xxjbF1gnPHPBRzEcn07tyXRq2Y8/RQ5lSFkZbfR1qvNHllYwXB41znFgZifuuttyrm0g3UBa3epA2uXr26edWrXrV9nUpZjoyfk1aOo/dc3k1eWVSyMZvLv/71r92WyPKpqQuy8WmQHZHrAkOy8WhwXnkf9FxnmhVznqlLl3o20nRgIs9jXRB5HupCROGlbmDgbPZzILekSvbt28fHP/7xzf333795+umndykiy0Yxl5549NFHNxcvXty+ToW6wATpffD32Yp5BzBmfuHCBcfMpRsUc+mJ2glwzKkamziNkMfcq15p1htQKLkA2K75Jxxns0tvKObSEzViTo/tM888s+1Spzt9jTTpDRDtsQfHzO1mV8ylN6gPIr1QK+alNvC+JgBcGk16g1iGVk5iII21hHNQzKU3WhNzZg6LzKVGzHnIWL7/0BDOhTFxeg00KeYUwNBzdmPt4BwUc+mN4+pCOLNsMUmIiIWGMWn0gtFYDso82NDkouwwsbGGdu5p4zzxJEfSInKKyUk02Es4hs+KfHN756RtasQcwY57iXuZ83A/0vXO9hpo8irjca6loJPGvjko5tIbxzmpMlLGuVGnMOpRCDTimEVyLF8JAnuosOJgOT5gOzcgIH+HDEIf33XKZ8qyqJ0AB4yXR8OR7ZoAcGk0eZWxnnzI5naZKObSG9SHQ0EMo+6EeGci8i3J+UrOQsxxxkTr0ZhQzPulRsxpcNII5V7hHHFv8TqlniyZZq9ySNBJG4oQDgExd2ma9MQUJ4WTy7N8y8ic90N1q8yXyc6T1+jmHGKumPMdicyDLOZ8JkZXKuAfIioLU/iXQ42Yc+/FvZgbn9xj5X3WK003WXAiVEZszKEcyoc//OHNfffdt3nyySd3KSLLBsd1CAhi2XWO88vCNxaVl/nGwGFyvjHminkWb4j3+ANEPhogXA/5SSeNSG3omqRdnnjiic073/nO7atMZ3H9D2tpZYkcx6FiHhOBghC7EEleOVcZWZf5jmNIjIM5Yo4wE21lyMf3ouGQv++QmDPHRtYF9wH3bDT41kQzYk7XSHSPUGGHjAp6qAMT6Z1D6gJOrRTEEO8M9SuL61C+4yjFOHOomGeBxh+Ugkw+0smLP8jQi8A5MLaHhg2kbeaWGfly+YflLvfeaUYZ48fP22M2h4ceemhzdHS0+dznPrdLEVk2h9QFxK8UxIhiI+rmPZFuFuKhfGUjgDwR/SCu+8S/FHPOzfGRny7xsps+7w84R3xvnHc4a447dEhA2oQxc3z0nDHzWNo4ZGWjsVeaEXMqaFRSCoBWNxU3W01k7mx26Y3j6kKI9FC0g3gilpyD1+zwxvKVYp4jIepnjqozcT6Oi3Fszp0dMHU758cXlOJMXo4N0adBEJ+NmMdnhK0pKuuB2qVplD/3SG4Aco/E/dI7zYh5Zl9Lam4rSzGX3sCB9UpeW34IiH8WbxoLPf8+PVIr5kONSdLWch8sSszHWv6HoJhLb/TqpBDiqdEUPiNH8vQirCUi64UaMafsh3qguAf2Df/0RJPeYMxJ0VKf23WmmEtv9CrmdI1Orec09HO3f9ltL+1TI+ZjcyYQ8ik9PEumGW9At1qMjVOgsZ3NMXOR/2NuXRBpkRoxh6HIfE005Q3oKqMw99ncLhPFXHqD+iDSC7Vivnaa8wYxY3UoMid6n9t1pphLbyjm0hM1Ys6wTOhGROikjY2l90iT3qBc33oSIOasYVTMpRcUc+mJGjEnXxjDsTmNIHANLMob1LSwEPEHHnhg8/3vf3+XIrJscFQivfDDH/5w88gjj2xfp0JETiTOUC1DsQSEsebc2eznCIUwVAB0meQHAoisGcVc5Hl4zgBCzpJEDHHnlfS11JMmrxIhH1ojSmQ+tPzgUP70pz/ttkSWj2IuPfGb3/xm87WvfW37OhU0g/owZEbm5wgFMDTRjTT2zeHSpUv+n7l0xdy6INIijJkzSbl2zDwbQWE8Jrx3mvQGFECeBEfXOl3vpFNAc3A2u/TG3Log0iK1s9mjiz1sbTTpDfatN587M1Exl96gPoj0guvM62jWG8S6wWw1awYVc+kN6oRIL9SIOQHgIRx63BJp2hvQvR4zEmufs6yYS28o5tITtevMWV8eDxgbsprHgS+BRV0ZUTmFMgfFXHpDMZeeqBXzQ61XmryyoQLINgfFXHpjbl0QaZHTjszDekUxF1koc+uCSIucxZh5zzQr5oyTl0sNmAA397ntiLnrzKUnFHPpCcQcHz1HzKVRMd/H3Kf58LzfT3/605uf//znuxSRZaOYS088++yzm2vXrm1fp+K/pjUq5uUYR1g8sk9EFHORgLoQ5r+mNUQumNIQ9Tn84Q9/2Hz3u9+d1eoTaRHqg0gvfOtb39o8/PDD29epoAv+a1qD4KTKmYkUElbz0JgXv/jFjplLNyjm0hM1E+D817RGxfw0ZiY6m116QzGXnqgR8xiCHTIj8zMmWlT7jIKZ+3/mirn0BvVBpBdq15kPmf+adg4MFcSQ1SxNU8ylJ6gPIr1QI+b+a9oCxTxmKk5FMW+PofLVptnly5d3v6bIsqkRc2lMzONBMbSyWE5QtrRqHxqjmLcFZS7zuX79+m5LZPmclpjP1Yyl0Yw3zZPeGOcYmrVO2tzJDIp5eyjmIhLUiDn/qkkAmFdAhXFOlqn1TpPelB8fcc9/exqFNVcAFPP2UMxFJKgR832z2cNOY5VUSzTpTUO0h4yW1hwQ89tuu00xbwjKU0QEEPOjo6NZYo4vGfvXtNANrOenwTXpTelOHxJ0CmPuQ2P+9re/bX7yk5/s3kkLUKYiIsFc/848q7Gu9LX4maavkoKNyW9z15dLu5x2JWPCpIj0Tzksm1HMG2GsgKbyhS98YdvV/uMf/3iXIudNTSXjvijzR5daWF7GSMMw9jO+NnZfkc4ETI6jpY+xTVrkiV6jocmYHMPnRD4aoiJyPF/96lc3DzzwwPZ1KtS1oW520tgHrJbq+QEyTYo5jpduEwohCgJIm9sNg5AzHuOYeTvksp0C9wBRd5mfyjsmnghwROrcR/tWRdDK51wB2+XkGT576LP4nOju2/d9ROSF1EyAI98+y8f0SpNXloU8//jhxOfgbPb2mFuxuD8QyTL/PvEkso593EfkHYvO54o556WREA1OxVzkcGrFfGwCHAb4DaxXmhTz7GjZDhg3z++noJi3x5yyRByjQpb5aejFEpXclc5reSzvx4R2rpgTkefZsuSLY/g+WHTzcQ3RnR+m8MuaqRHzsn6ukXnKeMrg5OKpPRQukQ6OMhz1HBTz9phaltwHWWTj3sgCGlC5uY8AkSw/i/cnLeZZvCHe0wjlO0bEHo0L0kkjooiueZG1UiPmAXWKOhf1bk00KeY4Tgp1yIYc9yEo5u1BeU5h7L7IwpthH5U6xDPEFGLfEHPEHMdBYzNDPoQ6T56DITFfyyMnRcaoEXPqEb1d5M/Wc7d6SZNiDkMFg3PMDnkKinl7UKY1HJef/SG4eZt7iPdjLfdDxTwLNPdrKcjkI528CHYmJvBhbM+9r0V6oUbMh/QibC2C3qyYAw4OB4yF4y2d6qEo5u1BRauB/FmQiYDzfZIjZQQzJk8iulmsS0ox53jOFeemSzy68IO8P+AcMUbOZ4dT4bj4LiLyPDVinodmA/SDtLKu9krTYl6CE5wrAIp5e9SIOcMt5M+iyDZpGEKaI2fuHdLYR5Sc92VIp/JzXIxj4xTi84byI9ilOJOXY8OR4FR4z3fgu8RnhK0lehAZo0bMyTfUu0Ua+9ZAU1cZTpHIqCwYnGftBLhbb71VMW+IXioZQj9lAhv3eRbvNTkckTEeffTRzcWLF7evU6GBjT6gHdlIy71sPdOMB8HB4dDC8kS3iGrC5vLPf/5ztyUtUFOWrYAQT+3Gw8nkSJ5hpLV0BYqcBtShrBFh1KuxXrjeaMabRhdoNgohd51iOELpA8pz6dDQnNpFXt7X+7r9ReQwqEMEgWgJxvaa6lUz3hSnxo/PeCLGdjg7jO6SmI08h0984hObN73pTZunn356lyLnDeUqIgJXr17d3HvvvdvXqezThhrdWBJNiTkiHrAdQk4UMzS5YQqMmV+4cMEx84ZQzEUkqJ0ARw9ZHi/HSFuLn2lKzEtIK5cbzC0YZ7O3x1oqmYgcT62Y77M10JSYl62qMi263uegmLfHWiqZiBxPrZjHzPVspPO6BpoS80NtDop5e8wtSxHpjxoxJ9gbgglwY/t6QzGXc2NuWYpIf9RG5jzrgclu2XwC3DlAYbDWvCyMbLEWfQ6KeXso5iISnNaYuWJ+xhw6rjF3/EMxbw8qmogInIaYI+RTns64ZFbjTRFzl6a1BZVNRARqxJwgr3b58tJZjTd9+OGHN695zWs2Tz755C5FzhvFXESCxx9/fPOOd7xj+yrT0ZvKuaGYi4icDM17U59Z3S+KuYhkfvvb3+62ZCpNelPGPuIxfNnhkzZ3XOTy5cvbMfPHHntslyLnjWIuIgFj5kxSnjNmXq58WiNNetMs5NnhI+T5ryOn4Gz29lDMRSSomQDHg2HIy+z1/AjwrCUn8R8fLdOkN+WHj+51toP485U5KObtMbcsRaQ/asQcbeBxrlmss5DzN8MIPWm90qQ3za0rCoICYq0ghTVXABTz9phbliLSHzVizv928FCxIP/rZgg43e89P0CmSW8aXSZDRqHNQTFvD8pTRARqxLz0JfGnXFiO1nv2Oc1eWTlujtU8GEAxb4+eK5aITKNWzEMbeCUCJy0Hf0TmPf+DWtPelEKJ2Yl0m9SgmLeHYi4iQY2YM7kN4UYrGB/nPFjoBlpCes9LnVfjTRXz9lDMRSSoEXNEOqLxsBgr5zX2OQHujGHMPP8HbXS5MwFubssKMT86OlLMG4IyFRGBGjEHtIEIna70tfy5SqZJb0qBhpjHZDiEnIKiq2QOX/nKV252w0gbKOYiEly7dm1z5cqV7etJkted90yzYs4YRywvoIskxj4UgH6wLEXkJCAqJ1gjKi8NP7OGSL1ZMWfNYExkiCidAqsZ8/jlL3+52zoZ+G5anb397W/f/ZoismYI2J566qlZk53jGST7LA/d9kiTYh5j5Bgtq4Bu9rldJpcuXXICXGNQviIiwJg5Pnru0jSCvzIqx0JHsLxUrTea9aZE4eX4dixTm4Oz2dvj+vXruy0RWTs1E+AIAMe60tcSNKwmNFLMRUTa5SRmsw/Re/d60HRknic0sD1WWIegmIuItEutmAPj7dGDG0+EWwtNijmiXT4AIMxudhGR/qgRc4Q7xsez9fyQmJImxZxCYXYi3SPZSJu7zlwxFxFplxoxp+e2FPIwu9nPEQpgqIuENPbNoXcxZ6a/iMhSqRFz8hHsMQku6wSrn+jlXQNNijk/PoVQCnpNwZy1mDNUEN0+cZMF+/aRVtrQLM2yS2msxyIPWXAejG3SYg5CtGr5LiXxXSPf3GEOEZF91Ip5Xp/Oe8B/xXbvNHmVeZ15aXPHQBDzs3w2O981xJLvnBsh+/aVETYiPdRLgcAeKqx0M3F8wHbZ9cR3GjofQh+NiSmfKSIyBcT8woULs8Qcv5n9ZOgFtpZx82abLEOCTtqQsB3CD37wg83Vq1dviuhZwtPshqJe2LcPER27Ec9CzPmt+W7xmyvmInJa/PWvf91873vf275OBR+VfeVJaMbSaLr/IS8zmPOIvxZArGk1DjUi9u0DhHTsusnHfm5YXvc1UuaKOY0JIvMgizmfiXENQKWJ7vwwhV9EzoPzCNrOmybFHIFAbMJCMKZCd03YBz7wgc173vOebXd7Tj9NED9Ejdfy5tq3DxDSsst9DH6j3FVfwn4+J2CbtMyQ+HJcTov3NDAQ+Wjx8v3JTzppDA1E17yIyCF8+9vf3vpkXo+j9F/7mHLskmlKzBEFhABhKI30qa2tV7/61TfzM/ntjjvueME577///t2Rp0d0/wyJ7b59XO+URgzXMxYJzxFzhJnIO0M+vhffN5fFkJiv5W8HReRkmDIBjuPwM/ikfcYxHLsGmrlKRCC6jceM/Rx3KF//+tc3L3vZy7Z5X/KSl2wFPc718pe//EyjRz5zTGzLfWyXQnoc+85/qJhngaaRUQoy+UgnL5UkQy8C58DYnlJOIiJTxXyKrYFmrhKB4Ecn6qMLl/dheTx2asT32te+9gWFGnbfffftjjgd+L4x3s015Oh73z5ANMvrRKj53kF5jn3iz/4s5pyb4yM/jZryO+T9AeeI3gIEm3IBjjt0SEBEZIiayJxtfFi8DyOtDDx6pRkxjwIZi+hIRzA4bgqPPfbY5s4777wp4hjd7V/+8pd3R5wOIbBx0+Wod98+trkBy9+hFPMcCfOb5HNk4nwcFz0RnDvWlmPld0CwS3EmL8eG6NMgiM9GzOMzwkLoRUQOYYqYlzow5gNJU8zPGApxTJACRIPjpnL33XffFBnsnnvu2e2RIfLa8kNA/LN401iYU04isl6miHkJ+cbEfC2+qCkxP4Q5BXPlypXNXXfdtc370pe+dPPJT35yt0dKEOKIvg+FnoYcydOLMPUcIrJuasQ8ejqJ0MOIyElj3xpoSswRhX1G9MdxU3n22WdvTn5DzP/973/v9kgJ3edTu8hp/eZu/7LbXkTkOGrEnN7BcqgPI23KqqAl05SYH2pzeOihh7aPCnQsV0SkPWrEnN5AhgYJ+mJuFbYWIYfViPmNGzc2t99++zZKFxGRtggx53Uq9CjmoT6EPPRiLQFcU2JOK4oW1pixf66Yi4hInyDYMbRHdI5OMNy3Js1o5ippSR3CoceJiMg6CMHOy2TZXtPKGsNcERFZNEThdLPHrHaic4gofQ0o5iIismjoYg8hz2PkiHkIe+8o5iIiIgtHMRcREVk4irmIiMjCUcxFREQWjmIuIiKycBRzERGRhaOYi4iILBzFXEREZOEo5iIiIgtHMRcREVk4irmIiMjCUcxFREQWjmIuIiKycBRzERGRhaOYi4iILBzFXEREZOEo5iIiIgtHMRcREVk4irmIiMjCUcxFREQWjmIuIiKycBRzERGRhaOYi4iILJrN5n/2WFshP310jgAAAABJRU5ErkJggg==" /></p><p>Anaemia symptoms and sequelae may vary with age, gender, and co-morbid medical conditions; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em>Treatment of symptomatic anaemia in chronic renal failure patients on haemodialysis</em></strong></p><p><em>&nbsp;</em></p><p>Anaemia symptoms and sequelae may vary with age, gender, and co-morbid medical conditions; a physician&rsquo;s evaluation of the individual patient&rsquo;s clinical course and condition is necessary.</p><p>&nbsp;</p><p>In paediatric patients the recommended haemoglobin concentration range is between 9.5&nbsp;g/dL to 11&nbsp;g/dL (5.9 to 6.8&nbsp;mmol/L). EPREX, ERYPO should be administered in order to increase haemoglobin to not greater than 11&nbsp;g/dL (6.8&nbsp;mmol/L). A rise in haemoglobin of greater than 2&nbsp;g/dL (1.25&nbsp;mmol/L) over a four&nbsp;week period should be avoided. If it occurs, appropriate dose adjustment should be made as provided.</p><p>&nbsp;</p><p>Patients should be monitored closely to ensure that the lowest approved dose of EPREX, ERYPO is used to provide adequate control of anaemia and of the symptoms of anaemia.</p><p>&nbsp;</p><p>Treatment with EPREX, ERYPO is divided into two stages &ndash; correction and maintenance phase.</p><p>&nbsp;</p><p>In paediatric patients on haemodialysis where intravenous access is readily available, administration by the intravenous route is preferable.</p><p>&nbsp;</p><p><em><u>Correction phase</u></em></p><p>&nbsp;</p><p>The starting dose is 50&nbsp;IU/kg intravenously, 3&nbsp;times per week.</p><p>&nbsp;</p><p>If necessary, increase or decrease the dose by 25&nbsp;IU/kg (3&nbsp;times per week) until the desired haemoglobin concentration range of between 9.5&nbsp;g/dL to 11&nbsp;g/dL (5.9 to 6.8&nbsp;mmol/L) is achieved (this should be done in steps of at least four&nbsp;weeks).</p><p>&nbsp;</p><p><em><u>Maintenance phase</u></em></p><p>&nbsp;</p><p>Appropriate adjustment of the dose should be made in order to maintain haemoglobin levels within the desired concentration range between 9.5&nbsp;g/dL to 11&nbsp;g/dL (5.9 to 6.8&nbsp;mmol/L).</p><p>&nbsp;</p><p>Generally, children under 30&nbsp;kg require higher maintenance doses than children over 30&nbsp;kg and adults.</p><p>Paediatric patients with very low initial haemoglobin (&lt;&nbsp;6.8&nbsp;g/dL or &lt;&nbsp;4.25&nbsp;mmol/L) may require higher maintenance doses than patients whose initial haemoglobin is higher (&gt;&nbsp;6.8&nbsp;g/dL or &gt;&nbsp;4.25&nbsp;mmol/L).</p><p>&nbsp;</p><p><strong><em>Anaemia in chronic renal failure patients before initiation of dialysis or on peritoneal dialysis</em></strong></p><p>&nbsp;</p><p>The safety and efficacy of EPREX, ERYPO in chronic renal failure patients with anaemia before initiation of dialysis or on peritoneal dialysis have not been established.&nbsp; Currently available data for subcutaneous use of EPREX, ERYPO in these populations are described in section 5.1 but no recommendation on posology can be made.</p><p>&nbsp;</p><p><strong><em>Treatment of paediatric patients with chemotherapy-induced anaemia</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>The safety and efficacy of EPREX, ERYPO in paediatric patients receiving chemotherapy have not been established (see section 5.1).</p><p>&nbsp;</p><p><strong><em>Treatment of paediatric surgery patients in an autologous predonation programme</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>The safety and efficacy of EPREX, ERYPO in paediatrics have not been established. No data are available.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em>Treatment of paediatric patients scheduled for major elective orthopaedic surgery</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>The safety and efficacy of EPREX, ERYPO in paediatrics have not been established. No data are available.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Precautions to be taken before handling or administering the medicinal product.</p><p>&nbsp;</p><p>Before use, leave the EPREX, ERYPO syringe to stand until it reaches room temperature. This usually takes between 15 and 30&nbsp;minutes.</p><p><u>&nbsp;</u></p><p><strong><em>Treatment of symptomatic anaemia in adult chronic renal failure patients</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of EPREX, ERYPO by the intravenous route is preferable.</p><p>&nbsp;</p><p>Where intravenous access is not readily available (patients not yet undergoing dialysis and peritoneal dialysis patients) EPREX, ERYPO may be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><strong><em>Treatment of adult patients with chemotherapy-induced anaemia</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>EPREX, ERYPO should be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><strong><em>Treatment of adult surgery patients in an autologous predonation programme</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>EPREX, ERYPO should be administered by the intravenous route.</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em>Treatment of adult patients scheduled for major elective orthopaedic surgery</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>EPREX, ERYPO should be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><strong><em>Treatment of adult patients</em></strong> <strong><em>with low- or intermediate-1-risk MDS</em></strong></p><p>&nbsp;</p><p>EPREX, ERYPO should be administered as a subcutaneous injection.</p><p>&nbsp;</p><p><strong><em>Treatment of symptomatic anaemia in paediatric chronic renal failure patients on haemodialysis</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>In paediatric patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of EPREX, ERYPO by the intravenous route is preferable.</p><p>&nbsp;</p><p><strong><em>Intravenous administration</em></strong></p><p><strong>&nbsp;</strong></p><p>Administer over at least one to five minutes, depending on the total dose. In haemodialysed patients, a bolus injection may be given during the dialysis session through a suitable venous port in the dialysis line. Alternatively, the injection can be given at the end of the dialysis session via the fistula needle tubing, followed by 10&nbsp;mL of isotonic saline to rinse the tubing and ensure satisfactory injection of the product into the circulation (see Posology, <strong><em>Adult haemodialysis patients</em></strong>).</p><p>&nbsp;</p><p>A slower administration is preferable in patients who react to the treatment with &ldquo;flu-like&rdquo; symptoms (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Do not administer EPREX, ERYPO by intravenous infusion or in conjunction with other drug solutions.</p><p>&nbsp;</p><p><strong><em>Subcutaneous administration</em></strong></p><p>&nbsp;</p><p>A maximum volume of 1&nbsp;mL at one injection site should generally not be exceeded. In case of larger volumes, more than one site should be chosen for the injection.</p><p>&nbsp;</p><p>The injections should be given in the limbs or the anterior abdominal wall.</p><p>&nbsp;</p><p>In those situations in which the physician determines that a patient or caregiver can safely and effectively administer EPREX, ERYPO subcutaneously themselves, instruction as to the proper dosage and administration should be provided.</p><p>&nbsp;</p><p>As with any other injectable product, check that there are no particles in the solution or change in colour.</p><p>&nbsp;</p><p><strong><em>Graduation marks</em></strong></p><p>The syringe label contains numbered graduation marks to provide for the administration of a part of the dose (see Section 6.6). However the product is for single use only. Only one dose of EPREX, ERYPO from each syringe should be taken.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive EPREX, ERYPO or any other erythropoietin (see section 4.4 - Pure Red Cell Aplasia).

Uncontrolled hypertension.

All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with EPREX, ERYPO.

The use of EPREX, ERYPO in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.

Surgery patients who for any reason cannot receive adequate antithrombotic prophylaxis.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>&nbsp;</p><p>In all patients receiving epoetin alfa, blood pressure should be closely monitored and controlled as necessary. Epoetin alfa should be used with caution in the presence of untreated, inadequately treated or poorly controllable hypertension. It may be necessary to add or increase anti-hypertensive treatment. If blood pressure cannot be controlled, epoetin alfa treatment should be discontinued.</p><p>&nbsp;</p><p>Hypertensive crisis with encephalopathy and seizures, requiring the immediate attention of a physician and intensive medical care, have occurred also during epoetin alfa treatment in patients with previously normal or low blood pressure. Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Epoetin alfa should be used with caution in patients with epilepsy, history of seizures, or medical conditions associated with a predisposition to seizure activity such as CNS infections and brain metastases.</p><p>&nbsp;</p><p>Epoetin alfa should be used with caution in patients with chronic liver failure. The safety of epoetin alfa has not been established in patients with hepatic dysfunction.</p><p>&nbsp;</p><p>An increased incidence of thrombotic vascular events (TVEs) has been observed in patients receiving ESAs (see section&nbsp;4.8). These include venous and arterial thromboses and embolism (including some with fatal outcomes), such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, and myocardial infarction. Additionally, cerebrovascular accidents (including cerebral infarction, cerebral haemorrhage and transient ischaemic attacks) have been reported.</p><p>&nbsp;</p><p>The reported risk of these TVEs should be carefully weighed against the benefits to be derived from treatment with epoetin alfa particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs (e.g., deep venous thrombosis, pulmonary embolism, and cerebral vascular accident).</p><p>&nbsp;</p><p>In all patients, haemoglobin levels should be closely monitored due to a potential increased risk of thromboembolic events and fatal outcomes when patients are treated at haemoglobin levels above the concentration range for the indication of use.</p><p>&nbsp;</p><p>There may be a moderate dose-dependent rise in the platelet count within the normal range during treatment with epoetin alfa. This regresses during the course of continued therapy. In addition, thrombocythaemia above the normal range has been reported. It is recommended that the platelet count is regularly monitored during the first 8&nbsp;weeks of therapy.</p><p>&nbsp;</p><p>All other causes of anaemia (iron, folate or Vitamin B<sub>12</sub> deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be evaluated and treated prior to initiating therapy with epoetin alfa, and when deciding to increase the dose. In most cases, the ferritin values in the serum fall simultaneously with the rise in packed cell volume. In order to ensure optimum response to epoetin alfa, adequate iron stores should be assured and iron supplementation should be administered if necessary (see section&nbsp;4.2):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For chronic renal failure patients, iron supplementation (elemental iron 200 to 300&nbsp;mg/day orally for adults and 100 to 200&nbsp;mg/day orally for paediatrics) is recommended if serum ferritin levels are below 100&nbsp;ng/mL.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For cancer patients, iron supplementation (elemental iron 200 to 300&nbsp;mg/day orally) is recommended if transferrin saturation is below 20%.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients in an autologous predonation programme, iron supplementation (elemental iron 200&nbsp;mg/day orally) should be administered several weeks prior to initiating the autologous predeposit in order to achieve high iron stores prior to starting epoetin alfa therapy, and throughout the course of epoetin alfa therapy.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For patients scheduled for major elective orthopaedic surgery, iron supplementation (elemental iron 200&nbsp;mg/day orally) should be administered throughout the course of epoetin alfa therapy. If possible, iron supplementation should be initiated prior to starting epoetin alfa therapy to achieve adequate iron stores.</p><p>&nbsp;</p><p>Very rarely, development of or exacerbation of porphyria has been observed in epoetin alfa-treated patients. Epoetin alfa should be used with caution in patients with porphyria.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment. More severe cases have been observed with long-acting epoetins.</p><p>&nbsp;</p><p>At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, EPREX, ERYPO should be withdrawn immediately and an alternative treatment considered.</p><p>&nbsp;</p><p>If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of EPREX, ERYPO, treatment with EPREX, ERYPO must not be restarted in this patient at any time.</p><p>&nbsp;</p><p><em>In order to improve the traceability of </em>erythropoiesis-stimulating agents (ESAs), the trade name and the batch number of the administered ESA should be clearly recorded (or stated) in the patient file.<em>&nbsp; </em></p><p>&nbsp;</p><p><em>Patients should only be switched from one ESA to another under appropriate supervision. </em></p><p>&nbsp;</p><p><u>Pure Red Cell Aplasia</u></p><p>&nbsp;</p><p>Antibody-mediated pure red cell aplasia (PRCA) has been reported after months to years of epoetin alfa treatment.</p><p>&nbsp;</p><p>Cases have also been reported in patients with hepatitis C treated with interferon and ribavirin, when ESAs are used concomitantly. Epoetin alfa is not approved in the management of anaemia associated with hepatitis C.</p><p>&nbsp;</p><p>In patients developing sudden lack of efficacy defined by a decrease in haemoglobin (1 to 2&nbsp;g/dL per month) with increased need for transfusions, a reticulocyte count should be obtained and typical causes of non-response (e.g. iron, folate or Vitamin B<sub>12</sub> deficiency, aluminium intoxication, infection or inflammation, blood loss, haemolysis and bone marrow fibrosis of any origin) should be investigated.</p><p>&nbsp;</p><p>A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin alfa and perform anti-erythropoietin antibody testing. A bone marrow examination should also be considered for diagnosis of PRCA.</p><p>&nbsp;</p><p>No other ESA therapy should be commenced because of the risk of cross-reaction.</p><p>&nbsp;</p><p><u>Treatment of symptomatic anaemia in adult and paediatric chronic renal failure patients</u></p><p>&nbsp;</p><p>Chronic renal failure patients being treated with epoetin alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter.</p><p>&nbsp;</p><p>In chronic renal failure patients the<strong><em> </em></strong>rate of increase in haemoglobin should be approximately 1&nbsp;g/dL (0.62&nbsp;mmol/L) per month and should not exceed 2&nbsp;g/dL (1.25&nbsp;mmol/L) per month to minimise risks of an increase in hypertension.</p><p>&nbsp;</p><p>In patients with chronic renal failure, maintenance haemoglobin concentration should not exceed the upper limit of the haemoglobin concentration range as recommended in section&nbsp;4.2. In clinical trials, an increased risk of death and serious cardiovascular events was observed when ESAs were administered to achieve a haemoglobin concentration level of greater than 12&nbsp;g/dL (7.5&nbsp;mmol/L).</p><p>&nbsp;</p><p>Controlled clinical trials have not shown significant benefits attributable to the administration of epoetins when haemoglobin concentration is increased beyond the level necessary to control symptoms of anaemia and to avoid blood transfusion.</p><p>&nbsp;</p><p>Caution should be exercised with escalation of EPREX, ERYPO doses in patients with chronic renal failure since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events. In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see section 4.2 and 5.1).</p><p>&nbsp;</p><p>Chronic renal failure patients treated with epoetin alfa by the subcutaneous route should be monitored regularly for loss of efficacy, defined as absent or decreased response to epoetin alfa treatment in patients who previously responded to such therapy. This is characterised by a sustained decrease in haemoglobin despite an increase in epoetin alfa dosage (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Some patients with more extended dosing intervals (greater than once weekly) of epoetin alfa may not maintain adequate haemoglobin levels (see section&nbsp;5.1) and may require an increase in epoetin alfa dose. Haemoglobin levels should be monitored regularly.</p><p>&nbsp;</p><p>Shunt thromboses have occurred in haemodialysis patients, especially in those who have a tendency to hypotension or whose arteriovenous fistulae exhibit complications (e.g. stenoses, aneurysms, etc.). Early shunt revision and thrombosis prophylaxis by administration of acetylsalicylic acid, for example, is recommended in these patients.</p><p>&nbsp;</p><p>Hyperkalaemia has been observed in isolated cases though causality has not been established. Serum electrolytes should be monitored in chronic renal failure patients. If an elevated or rising serum potassium level is detected, then in addition to appropriate treatment of the hyperkalaemia<strong><em>, </em></strong>consideration should be given to ceasing epoetin alfa administration until the serum potassium level<strong><em> </em></strong>has been corrected.</p><p>&nbsp;</p><p>An increase in heparin dose during haemodialysis is frequently required during the course of therapy with epoetin alfa as a result of the increased packed cell volume. Occlusion of the dialysis system is possible if heparinisation is not optimum.</p><p>&nbsp;</p><p>Based on information available to date, correction of anaemia with epoetin alfa in adult patients with renal insufficiency not yet undergoing dialysis does not accelerate the rate of progression of renal insufficiency.</p><p>&nbsp;</p><p><u>Treatment of patients with chemotherapy-induced anaemia</u></p><p>&nbsp;</p><p>Cancer patients being treated with epoetin alfa should have haemoglobin levels measured on a regular basis until a stable level is achieved, and periodically thereafter.</p><p>&nbsp;</p><p>Epoetins are growth factors that primarily stimulate red blood cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells. As with all growth factors, there is a concern that epoetins could stimulate the growth of tumours.</p><p>&nbsp;</p><p>The role of ESAs on tumour progression or reduced progression-free survival cannot be excluded. In controlled clinical studies, use of epoetin alfa and other ESAs have been associated with decreased locoregional tumour control or decreased overall survival:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased locoregional control in patients with advanced head and neck cancer receiving radiation therapy when administered to achieve a haemoglobin concentration level of greater than 14&nbsp;g/dL (8.7&nbsp;mmol/L),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortened overall survival and increased deaths attributed to disease progression at 4&nbsp;months in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 12 to 14&nbsp;g/dL (7.5 to 8.7&nbsp;mmol/L),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased risk of death when administered to achieve a haemoglobin concentration level of 12&nbsp;g/dL (7.5&nbsp;mmol/L) in patients with active malignant disease receiving neither chemotherapy nor radiation therapy. ESAs are not indicated for use in this patient population,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an observed 9% increase in risk for PD or death in the epoetin alfa plus SOC group from a primary analysis and a 15% increased risk that cannot be statistically ruled out in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 10 to 12 g/dL (6.2 to 7.5 mmol/L).</p><p>&nbsp;</p><p>In view of the above, in some clinical situations blood transfusion should be the preferred treatment for the management of anaemia in patients with cancer. The decision to administer recombinant erythropoietin treatment should be based on a benefit-risk assessment with the participation of the individual patient, which should take into account the specific clinical context. Factors that should be considered in this assessment should include the type of tumour and its stage; the degree of anaemia; life-expectancy; the environment in which the patient is being treated; and patient preference (see section&nbsp;5.1).</p><p>&nbsp;</p><p>In cancer patients receiving chemotherapy, the 2 to 3 week delay between ESA administration and the appearance of erythropoietin-induced red cells should be taken into account when assessing if epoetin alfa therapy is appropriate (patient at risk of being transfused).</p><p><u>&nbsp;</u></p><p><u>Surgery patients in autologous predonation programmes</u></p><p>&nbsp;</p><p>All special warnings and special precautions associated with autologous predonation programmes, especially routine volume replacement, should be respected.</p><p>&nbsp;</p><p><u>Patients scheduled for major elective orthopaedic surgery</u></p><p>&nbsp;</p><p>Good blood management practices should always be used in the perisurgical setting.</p><p>&nbsp;</p><p>Patients scheduled for major elective orthopaedic surgery should receive adequate antithrombotic prophylaxis, as thrombotic and vascular events may occur in surgical patients, especially in those with underlying cardiovascular disease. In addition, special precaution should be taken in patients with predisposition for development of DVTs. Moreover, in patients with a baseline haemoglobin of &gt;&nbsp;13&nbsp;g/dL, the possibility that epoetin alfa treatment may be associated with an increased risk of postoperative thrombotic/vascular events cannot be excluded. Therefore, epoetin alfa should not be used in patients with baseline haemoglobin &gt;&nbsp;13&nbsp;g/dL.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No evidence exists that indicates that treatment with epoetin alfa alters the metabolism of other drugs.</p><p>Drugs that decrease erythropoiesis may decrease the response to epoetin alfa.</p><p>&nbsp;</p><p>Since cyclosporin is bound by RBCs there is potential for a drug interaction. If epoetin alfa is given concomitantly with cyclosporin, blood levels of cyclosporin should be monitored and the dose of cyclosporin adjusted as the haematocrit rises.</p><p>&nbsp;</p><p>No evidence exists that indicates an interaction between epoetin alfa and G-CSF or GM-CSF with regard to haematological differentiation or proliferation of tumour biopsy specimens <em>in vitro</em>.</p><p>&nbsp;</p><p>In female adult patients with metastatic breast cancer, subcutaneous co-administration of 40,000&nbsp;IU/mL epoetin alfa with trastuzumab 6&nbsp;mg/kg had no effect on the pharmacokinetics of trastuzumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no adequate and well-controlled studies in pregnant women. Studies in animals have shown reproduction toxicity (see section&nbsp;5.3).<strong> </strong>Consequently, epoetin alfa should be used in pregnancy only if the potential benefit outweighs the potential risk to the foetus. The use of epoetin alfa is not recommended in pregnant surgical patients participating in an autologous blood predonation.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>&nbsp;</p><p>It is not known whether exogenous epoetin alfa is excreted in human milk. Epoetin alfa should be used with caution in nursing women. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with epoetin alfa should be made taking into account the benefit of breast-feeding to the child and the benefit of epoetin alfa therapy to the woman.</p><p>&nbsp;</p><p>The use of epoetin alfa is not recommended in lactating surgical patients participating in an autologous blood predonation programme.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no studies assessing the potential effect of epoetin alfa on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Summary of Safety Profile</em></strong></p><p>&nbsp;</p><p>The most frequent adverse drug reaction during treatment with epoetin alfa is a dose-dependent increase in blood pressure or aggravation of existing hypertension. Monitoring of the blood pressure should be performed, particularly at the start of therapy (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The most frequently occurring adverse drug reactions observed in clinical trials of epoetin alfa are diarrhoea, nausea, vomiting, pyrexia and headache. Influenza-like illness may occur especially at the start of treatment.</p><p>&nbsp;</p><p>Respiratory tract congestion, which includes events of upper respiratory tract congestion, nasal congestion and nasopharyngitis, have been reported in studies with extended interval dosing in adult patients with renal insufficiency not yet undergoing dialysis.</p><p>&nbsp;</p><p>An increased incidence of thrombotic vascular events (TVEs) has been observed in patients receiving ESAs (see section&nbsp;4.4).</p><p>&nbsp;</p><p><strong><em>Tabulated List of Adverse Reactions</em></strong></p><p>&nbsp;</p><p>Of a total 3,417&nbsp;subjects in 25 randomized, double-blinded, placebo or standard of care controlled studies, the overall safety profile of EPREX was evaluated in 2,094 anaemic subjects. Included were 228 epoetin alfa-treated CRF subjects in 4 chronic renal failure studies (2 studies in predialysis [N&nbsp;=&nbsp;131 exposed CRF subjects] and 2 in dialysis [N&nbsp;=&nbsp;97 exposed CRF subjects]; 1,404 exposed cancer subjects in 16 studies of anaemia due to chemotherapy; 147 exposed subjects in 2 studies for autologous blood donation;&nbsp;213 exposed subjects in 1 study in the perisurgical period, and 102 exposed subjects in 2 MDS studies. Adverse drug reactions reported by &sup3;1% of subjects treated with epoetin alfa in these trials are shown in the table below.</p><p>&nbsp;</p><p>Frequency estimate: Very common (&ge;&nbsp;1/10), Common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), Uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), Rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), Very Rare (&lt;&nbsp;1/10,000), Not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>MedDRA System Organ Classification (SOC)</strong></p></td><td><p><strong>Adverse Reaction (Preferred Term Level)</strong></p></td><td><p><strong>Frequency</strong></p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>Pure red cell aplasia<sup>3</sup>, Thrombocythemia</p></td><td><p>Rare</p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Hyperkalaemia<sup>1</sup></p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>Immune system disorders</p></td><td><p>Hypersensitivity<sup>3</sup></p></td><td><p>Uncommon</p></td></tr><tr><td><p>Anaphylactic reaction<sup>3</sup></p></td><td><p>Rare</p></td></tr><tr><td rowspan="2"><p>Nervous system disorders</p></td><td><p>Headache</p></td><td><p>Common</p></td></tr><tr><td><p>Convulsion</p></td><td><p>Uncommon</p></td></tr><tr><td rowspan="2"><p>Vascular disorders</p></td><td><p>Hypertension, Venous and arterial thromboses<sup>2</sup></p></td><td><p>Common</p></td></tr><tr><td><p>Hypertensive crisis<sup>3</sup></p></td><td><p>Not known</p></td></tr><tr><td rowspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td><td><p>Cough</p></td><td><p>Common</p></td></tr><tr><td><p>Respiratory tract congestion</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Diarrhoea, Nausea, Vomiting</p></td><td><p>Very common</p></td></tr><tr><td rowspan="3"><p>Skin and subcutaneous tissue disorders</p></td><td><p>Rash</p></td><td><p>Common</p></td></tr><tr><td><p>Urticaria<sup>3</sup></p></td><td><p>Uncommon</p></td></tr><tr><td><p>Angioneurotic oedema<sup>3</sup></p></td><td><p>Not known</p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders</p></td><td><p>Arthralgia, Bone pain, Myalgia, Pain in extremity</p></td><td><p>Common</p></td></tr><tr><td><p>Congenital, familial and genetic disorders</p></td><td><p>Porphyria acute<sup>3</sup></p></td><td><p>Rare</p></td></tr><tr><td rowspan="3"><p>General disorders and administration site conditions</p></td><td><p>Pyrexia</p></td><td><p>Very common</p></td></tr><tr><td><p>Chills, Influenza like illness, Injection site reaction, Oedema peripheral</p></td><td><p>Common</p></td></tr><tr><td><p>Drug ineffective<sup>3</sup></p></td><td><p>Not known</p></td></tr><tr><td><p>Investigations</p></td><td><p>Anti-erythropoeitin antibody positive</p></td><td><p>Rare</p></td></tr><tr><td colspan="3"><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common in dialysis</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes arterial and venous, fatal and non fatal events, such as deep venous thrombosis, pulmonary emboli, retinal thrombosis, arterial thrombosis (including myocardial infarction), cerebrovascular accidents (including cerebral infarction and cerebral haemorrhage) transient ischaemic attacks, and shunt thrombosis (including dialysis equipment) and thrombosis within arteriovenous shunt aneurisms</p><p><sup>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Addressed in the subsection below and/or in section 4.4</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>Description of selected adverse reactions</em></strong></p><p>&nbsp;</p><p>Hypersensitivity reactions, including cases of rash (including urticaria), anaphylactic reactions, and angioneurotic oedema have been reported.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARs) including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which can be life-threatening or fatal, have been reported in association with epoetin treatment (see section 4.4).</p><p>&nbsp;</p><p>Hypertensive crisis with encephalopathy and seizures, requiring the immediate attention of a physician and intensive medical care, have occurred also during epoetin alfa treatment in patients with previously normal or low blood pressure. Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Antibody-mediated pure red cell aplasia has been very rarely reported in &lt;&nbsp;1/10,000 cases per patient year after months to years of treatment with EPREX, ERYPO (see section&nbsp;4.4). More cases have been reported with subcutaneous (SC) route of administration, compared with the IV route.</p><p>&nbsp;</p><p><strong><em>Adult patients</em></strong> <strong><em>with low- or intermediate-1-risk MDS</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>In the randomized, double-blind, placebo-controlled, multicenter study 4 (4.7%) subjects experienced TVEs (sudden death, ischemic stroke, embolism, and phlebitis). All TVEs occurred in the epoetin alfa group and in the first 24&nbsp;weeks of the study.&nbsp; Three were confirmed TVE and in the remaining case (sudden death), the thromboembolic event was not confirmed. Two subjects had significant risk factors (atrial fibrillation, heart failure and thrombophlebitis).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Paediatric population with chronic renal failure on haemodialysis</em></strong></p><p>&nbsp;</p><p>The exposure of paediatric patients with chronic renal failure on haemodialysis in clinical trials and post-marketing experience is limited. No paediatric-specific adverse reactions not mentioned previously in the table above, or any that were not consistent with the underlying disease were reported in this population.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions </u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The therapeutic margin of epoetin alfa is very wide. Overdosage of epoetin alfa may produce effects that are extensions of the pharmacological effects of the hormone. Phlebotomy may be performed if excessively high haemoglobin levels occur. Additional supportive care should be provided as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: anti-anaemic, ATC code: B03XA01.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Erythropoietin (EPO) is a glycoprotein hormone produced primarily by the kidney in response to hypoxia and is the key regulator of red blood cell (RBC) production. EPO is involved in all phases of erythroid development, and has its principal effect at the level of erythroid precursors. After EPO binds to its cell surface receptor, it activates signal transduction pathways that interfere with apoptosis and stimulates erythroid cell proliferation. Recombinant human EPO (epoetin alfa), expressed in Chinese hamster ovary cells, has a 165 amino acid sequence identical to that of human urinary EPO; the 2 are indistinguishable on the basis of functional assays. The apparent molecular weight of erythropoietin is 32,000 to 40,000&nbsp;dalton.</p><p>&nbsp;</p><p>Erythropoietin is a growth factor that primarily stimulates red cell production. Erythropoietin receptors may be expressed on the surface of a variety of tumour cells.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p><strong><em>Healthy volunteers</em></strong></p><p><u>&nbsp;</u></p><p>After single doses (20,000 to 160,000&nbsp;IU subcutaneously) of epoetin alfa, a dose‑dependent response was observed for the pharmacodynamic markers investigated including: reticulocytes, RBCs, and haemoglobin. A defined concentration-time profile with peak and return to baseline was observed for changes in percent reticulocytes. A less defined profile was observed for RBCs and haemoglobin. In general, all pharmacodynamic markers increased in a linear manner with dose reaching a maximum response at the highest dose levels.</p><p>&nbsp;</p><p>Further pharmacodynamic studies explored 40,000&nbsp;IU once&nbsp;weekly versus 150&nbsp;IU/kg 3 times per week. Despite differences in concentration‑time profiles the pharmacodynamic response (as measured by changes in percent reticulocytes, haemoglobin, and total RBCs) was similar between these regimens. Additional studies compared the 40,000&nbsp;IU once‑weekly regimen of epoetin alfa with biweekly doses ranging from 80,000 to 120,000&nbsp;IU subcutaneously. Overall, based on the results of these pharmacodynamic studies in healthy subjects, the 40,000&nbsp;IU once‑weekly dosing regimen seems to be more efficient in producing RBCs than the biweekly regimens despite an observed similarity in reticulocyte production in the once‑weekly and biweekly regimens.</p><p><u>&nbsp;</u></p><p><strong><em>Chronic renal failure</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Epoetin alfa has been shown to stimulate erythropoiesis in anaemic patients with CRF, including dialysis and pre-dialysis patients. The first evidence of a response to epoetin alfa is an increase in the reticulocyte count within 10&nbsp;days, followed by increases in the red cell count, haemoglobin and haematocrit, usually within 2 to 6&nbsp;weeks. The haemoglobin response varies between patients and may be impacted by iron stores and the presence of concurrent medical problems.</p><p>&nbsp;</p><p><strong><em>Chemotherapy-induced anaemia</em></strong></p><p>&nbsp;</p><p>Epoetin alfa administered 3&nbsp;times per week or once weekly has been shown to increase haemoglobin and decrease transfusion requirements after the first month of therapy in anaemic cancer patients receiving chemotherapy.</p><p>&nbsp;</p><p>In a study comparing the 150&nbsp;IU/kg, 3 times-per-week and 40,000&nbsp;IU, once-weekly dosing regimens in healthy subjects and in anaemic cancer subjects the time profiles of changes in percent reticulocytes, haemoglobin, and total red blood cells were similar between the two dosing regimens in both healthy and anaemic cancer subjects. The AUCs of the respective pharmacodynamic parameters were similar between the 150&nbsp;IU/kg, 3&nbsp;times-per-week and 40,000&nbsp;IU, once-weekly dosing regimens in healthy subjects and also in anaemic cancer subjects.</p><p>&nbsp;</p><p><strong><em>Adult surgery patients in an autologous predonation programme</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Epoetin alfa has been shown to stimulate red blood cell production in order to augment autologous blood collection, and to limit the decline in haemoglobin in adult patients scheduled for major elective surgery who are not expected to predeposit their complete perioperative blood needs. The greatest effects are observed in patients with low haemoglobin (&le;&nbsp;13&nbsp;g/dL).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Treatment of adult patients scheduled for major elective orthopaedic surgery</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>In patients scheduled for major elective orthopaedic surgery with a pretreatment haemoglobin of &gt;&nbsp;10 to &le;&nbsp;13&nbsp;g/dL, epoetin alfa has been shown to decrease the risk of receiving allogeneic transfusions and hasten erythroid recovery (increased haemoglobin levels, haematocrit levels, and reticulocyte counts).</p><p><strong><em>&nbsp;</em></strong></p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><strong><em>Chronic renal failure</em></strong></p><p><u>&nbsp;</u></p><p>Epoetin alfa has been studied in clinical trials in adult anaemic CRF patients, including haemodialysis and pre-dialysis patients, to treat anaemia and maintain haematocrit within a target concentration range of 30 to 36%.</p><p>&nbsp;</p><p>In clinical trials at starting doses of 50 to 150&nbsp;IU/kg, three times per week, approximately 95% of all patients responded with a clinically significant increase in haematocrit. After approximately two months of therapy, virtually all patients were transfusion-independent. Once the target haematocrit was achieved, the maintenance dose was individualised for each patient.</p><p>&nbsp;</p><p>In the three largest clinical trials conducted in adult patients on dialysis, the median maintenance dose necessary to maintain the haematocrit between 30 to 36% was approximately 75&nbsp;IU/kg given 3&nbsp;times per week.</p><p>&nbsp;</p><p>In a double-blind, placebo-controlled, multicentre, quality of life study in CRF patients on haemodialysis, clinically and statistically significant improvement was shown in the patients treated with epoetin alfa compared to the placebo group when measuring fatigue, physical symptoms, relationships and depression (Kidney Disease Questionnaire) after six months of therapy. Patients from the group treated with epoetin alfa were also enrolled in an open-label extension study which demonstrated improvements in their quality of life that were maintained for an additional 12&nbsp;months.</p><p>&nbsp;</p><p><strong><em>Adult patients with renal insufficiency not yet undergoing dialysis</em></strong></p><p>&nbsp;</p><p>In clinical trials conducted in patients with CRF not on dialysis treated with epoetin alfa, the average duration of therapy was nearly five months. These patients responded to epoetin alfa therapy in a manner similar to that observed in patients on dialysis. Patients with CRF not on dialysis demonstrated a dose-dependent and sustained increase in haematocrit when epoetin alfa was administered by either an intravenous or subcutaneous route. Similar rates of rise of haematocrit were noted when epoetin alfa was administered by either route. Moreover, epoetin alfa doses of 75 to 150&nbsp;IU/kg per week have been shown to maintain haematocrits of 36 to 38% for up to six&nbsp;months.</p><p>&nbsp;</p><p>In 2 studies with extended interval dosing of EPREX, ERYPO (3&nbsp;times per week, once weekly, once every 2&nbsp;weeks, and once every 4&nbsp;weeks) some patients with longer dosing intervals did not maintain adequate haemoglobin levels and reached protocol-defined haemoglobin withdrawal criteria (0% in once weekly, 3.7% in once-every-2-weeks, and 3.3% in the once-every-4-weeks groups).</p><p>&nbsp;</p><p>A randomized prospective trial (CHOIR) evaluated 1,432 anaemic chronic renal failure patients who were not undergoing dialysis. Patients were assigned to epoetin alfa treatment targeting a maintenance haemoglobin level of 13.5&nbsp;g/dL (higher than the recommended haemoglobin concentration level) or 11.3&nbsp;g/dL. A major cardiovascular event (death, myocardial infarction, stroke or hospitalization for congestive heart failure) occurred among 125 (18%) of the 715&nbsp;patients in the higher haemoglobin group compared to 97 (14%) among the 717&nbsp;patients in the lower haemoglobin group (hazard ratio [HR] 1.3, 95% CI: 1.0, 1.7, p&nbsp;=&nbsp;0.03).</p><p>&nbsp;</p><p>Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients). A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed (see section 4.2 and section 4.4).</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Treatment of patients with chemotherapy-induced anaemia</em></strong></p><p><u>&nbsp;</u></p><p>Epoetin alfa has been studied in clinical trials in adult anaemic cancer patients with lymphoid and solid tumors, and patients on various chemotherapy regimens, including platinum and non-platinum-containing regimens. In these trials, epoetin alfa administered 3 times per week and once weekly has been shown to increase haemoglobin and decrease transfusion requirements after the first month of therapy in anaemic cancer patients. In some studies, the double-blind phase was followed by an open-label phase during which all patients received epoetin alfa and a maintenance of effect was observed.</p><p>&nbsp;</p><p>Available evidence suggests patients with haematological malignancies and solid tumours respond equivalently to epoetin alfa therapy, and that patients with or without tumour infiltration of the bone marrow respond equivalently to epoetin alfa therapy. Comparable intensity of chemotherapy in the epoetin alfa and placebo groups in the chemotherapy trials was demonstrated by a similar area under the neutrophil time curve in patients treated with epoetin alfa and placebo-treated patients, as well as by a similar proportion of patients in groups treated with epoetin alfa and placebo-treated groups whose absolute neutrophil counts fell below 1,000 and 500&nbsp;cells/&mu;L.</p><p><u>&nbsp;</u></p><p>In a prospective, randomised, double-blind, placebo-controlled trial conducted in 375 anaemic patients with various non-myeloid malignancies receiving non-platinum chemotherapy, there was a significant reduction of anaemia-related sequelae (e.g. fatigue, decreased energy, and activity reduction), as measured by the following instruments and scales: Functional Assessment of Cancer Therapy-Anaemia (FACT-An) general scale, FACT-An fatigue scale, and Cancer Linear Analogue Scale (CLAS). Two other smaller, randomised, placebo-controlled trials failed to show a significant improvement in quality of life parameters on the EORTC-QLQ-C30 scale or CLAS, respectively.</p><p>&nbsp;</p><p>Survival and tumour progression have been examined in five large controlled studies involving a total of 2,833&nbsp;patients, of which four were double-blind placebo-controlled studies and one was an open-label study. The studies either recruited patients who were being treated with chemotherapy (two studies) or used patient populations in which ESAs are not indicated: anaemia in patients with cancer not receiving chemotherapy, and head and neck cancer patients receiving radiotherapy. The desired haemoglobin concentration level in two studies was &gt;&nbsp;13&nbsp;g/dL; in the remaining three studies it was 12 to 14&nbsp;g/dL. In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls. In the four placebo-controlled studies the hazard ratios for overall survival ranged between 1.25 and 2.47 in favour of controls. These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls. Overall survival outcome in the trials could not be satisfactorily explained by differences in the incidence of thrombosis and related complications between those given recombinant human erythropoietin and those in the control group.</p><p>&nbsp;</p><p>A patient-level data analysis has also been performed on more than 13,900 cancer patients (chemo-, radio-, chemoradio-, or no therapy) participating in 53 controlled clinical trials involving several epoetins. Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933&nbsp;patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441&nbsp;patients). Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section&nbsp;4.4).</p><p>&nbsp;</p><p>A randomised, open-label, multicentre study was conducted in 2,098 anaemic women with metastatic breast cancer, who received first line or second line chemotherapy. This was a non‑inferiority study designed to rule out a 15% risk increase in tumour progression or death of epoetin alfa plus standard of care (SOC) as compared with SOC alone. At the time of clinical data cutoff, the median progression free survival (PFS) per investigator assessment of disease progression was 7.4 months in each arm (HR 1.09, 95% CI: 0.99, 1.20), indicating the study objective was not met. Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%). At the final analysis, 1653 deaths were reported. Median overall survival in the epoetin alfa plus SOC group was 17.8&nbsp;months compared with 18.0 months in the SOC alone group (HR 1.07, 95% CI: 0.97, 1.18). The median time to progression (TTP) based on investigator-determined progressive disease (PD) was 7.5&nbsp;months in the epoetin alfa plus SOC group and 7.5&nbsp;months in the SOC group (HR 1.099, 95% CI: 0.998, 1.210). The median TTP based on IRC-determined PD was 8.0&nbsp;months in the epoetin alfa plus SOC group and 8.3&nbsp;months in the SOC group (HR 1.033, 95% CI: 0.924, 1.156).</p><p>&nbsp;</p><p><strong><em>Autologous predonation programme</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>The effect of epoetin alfa in facilitating autologous blood donation in patients with low haematocrits (&le;&nbsp;39% and no underlying anaemia due to iron deficiency) scheduled for major orthopaedic surgery was evaluated in a double-blind, placebo-controlled study conducted in 204&nbsp;patients, and a single-blind placebo controlled study in 55&nbsp;patients.</p><p>&nbsp;</p><p>In the double-blind study, patients were treated with epoetin alfa 600&nbsp;IU/kg or placebo intravenously once daily every 3 to 4&nbsp;days over 3&nbsp;weeks (total 6&nbsp;doses). On average, patients treated with epoetin alfa were able to predeposit significantly more units of blood (4.5&nbsp;units) than placebo-treated patients (3.0&nbsp;units).</p><p>&nbsp;</p><p>In the single-blind study, patients were treated with epoetin alfa 300&nbsp;IU/kg or 600&nbsp;IU/kg or placebo intravenously once daily every 3 to 4&nbsp;days over 3&nbsp;weeks (total 6&nbsp;doses). Patients treated with epoetin alfa were also able to predeposit significantly more units of blood (epoetin alfa 300&nbsp;IU/kg&nbsp;=&nbsp;4.4&nbsp;units; epoetin alfa 600&nbsp;IU/kg&nbsp;=&nbsp;4.7&nbsp;units) than placebo-treated patients (2.9&nbsp;units).</p><p>&nbsp;</p><p>Epoetin alfa therapy reduced the risk of exposure to allogeneic blood by 50% compared to patients not receiving epoetin alfa.</p><p>&nbsp;</p><p><strong><em>Major elective orthopaedic surgery</em></strong></p><p>&nbsp;</p><p>The effect of epoetin alfa (300&nbsp;IU/kg or 100&nbsp;IU/kg) on the exposure to allogeneic blood transfusion has been evaluated in a placebo-controlled, double-blind clinical trial in non-iron deficient adult patients scheduled for major elective orthopaedic hip or knee surgery. Epoetin alfa was administered subcutaneously for 10&nbsp;days prior to surgery, on the day of surgery, and for four days after surgery. Patients were stratified according to their baseline haemoglobin (&le;&nbsp;10&nbsp;g/dL, &gt;&nbsp;10 to &le;&nbsp;13&nbsp;g/dL and &gt;&nbsp;13&nbsp;g/dL).</p><p>&nbsp;</p><p>Epoetin alfa 300&nbsp;IU/kg significantly reduced the risk of allogeneic transfusion in patients with a pretreatment haemoglobin of &gt;&nbsp;10 to &le;&nbsp;13&nbsp;g/dL. Sixteen percent of epoetin alfa 300&nbsp;IU/kg, 23% of epoetin alfa 100&nbsp;IU/kg and 45% of placebo-treated patients required transfusion.</p><p>&nbsp;</p><p>An open-label, parallel-group trial in non-iron deficient adult subjects with a pretreatment haemoglobin of &ge;&nbsp;10 to &le;&nbsp;13&nbsp;g/dL who were scheduled for major orthopaedic hip or knee surgery compared epoetin alfa 300&nbsp;IU/kg subcutaneously daily for 10&nbsp;days prior to surgery, on the day of surgery and for four days after surgery to epoetin alfa 600&nbsp;IU/kg subcutaneously once weekly for 3&nbsp;weeks prior to surgery and on the day of surgery.</p><p>&nbsp;</p><p>From pretreatment to presurgery, the mean increase in haemoglobin in the 600&nbsp;IU/kg weekly group (1.44&nbsp;g/dL) was twice than that observed in the 300&nbsp;IU/kg daily group (0.73&nbsp;g/dL). Mean haemoglobin levels were similar for the two treatment groups throughout the postsurgical period.</p><p>&nbsp;</p><p>The erythropoietic response observed in both treatment groups resulted in similar transfusion rates (16% in the 600&nbsp;IU/kg weekly group and 20% in the 300&nbsp;IU/kg daily group).</p><p>&nbsp;</p><p><strong><em>Treatment of adult patients</em></strong> <strong><em>with low- or intermediate-1-risk MDS</em></strong></p><p>&nbsp;</p><p>A randomized, double-blind, placebo-controlled, multicenter study evaluated the efficacy and safety of epoetin alfa in adult anemic subjects with low- or intermediate-1-risk MDS.</p><p>&nbsp;</p><p>Subjects were stratified by serum erythropoetin (sEPO) level and prior transfusion status at screening.&nbsp; Key baseline characteristics for the &lt;200&nbsp;mU/mL stratum are shown in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><strong>Baseline Characteristics for Subjects with sEPO&lt; 200mU/mL at Screening</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>Randomized</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Epoetin alfa</p></td><td><p>Placebo</p></td></tr><tr><td><p>Total (N)<sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p></td><td><p>85<sup>a</sup></p></td><td><p>45</p></td></tr><tr><td><p>Screening sEPO &lt;200&nbsp;mU/mL (N)</p></td><td><p>71</p></td><td><p>39</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Hemoglobin (g/L)</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>N</p></td><td><p>71</p></td><td><p>39</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean</p></td><td><p>92.1 (8.57)</p></td><td><p>92.1 (8.51)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Median</p></td><td><p>94.0</p></td><td><p>96.0</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Range</p></td><td><p>(71, 109)</p></td><td><p>(69, 105)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 95% CI for mean</p></td><td><p>(90.1, 94.1)</p></td><td><p>(89.3, 94.9)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Prior Transfusions</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>N</p></td><td><p>71</p></td><td><p>39</p></td></tr><tr><td><p>Yes</p></td><td><p>31 (43.7%)</p></td><td><p>17 (43.6%)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &le; 2 RBC Units</p></td><td><p>16 (51.6%)</p></td><td><p>9 (52.9%)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;2 and &le;4 RBC Units</p></td><td><p>14 (45.2%)</p></td><td><p>8 (47.1%)</p></td></tr><tr><td><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &gt;4 RBC Units</p></td><td><p>1 ( 3.2%)</p></td><td><p>0</p></td></tr><tr><td><p>No</p></td><td><p>40 (56.3%)</p></td><td><p>22 (56.4%)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one subject did not have sEPO data</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>in the &ge;200&nbsp;mU/mL stratum there were 13 subjects in the epoetin alfa group and 6 subjects in the placebo group</p></td></tr></tbody></table><p>&nbsp;</p><p>Erythroid response was defined according to International Working Group (IWG) 2006 criteria as a haemoglobin increase &ge;&nbsp;1.5&nbsp;g/dL from baseline or a reduction of RBC units transfused by an absolute number of at least 4 units every 8&nbsp;weeks compared to the 8&nbsp;weeks prior to baseline, and a response duration of at least 8&nbsp;weeks.</p><p>&nbsp;</p><p>Erythroid response during the first 24&nbsp;weeks of the study was demonstrated by 27/85 (31.8%) of the subjects in the epoetin alfa group compared to 2/45 (4.4%) of the subjects in the placebo group (p&lt;0.001). All of the responding subjects were in the stratum with sEPO &lt;200&nbsp;mU/mL during screening. In that stratum, 20/40 (50%) subjects without prior transfusions demonstrated erythroid response during the first 24&nbsp;weeks, compared with 7/31 (22.6%) subjects with prior transfusions (two subjects with prior transfusion reached primary endpoint based on reduction of RBC units transfused by an absolute number of at least 4 units every 8&nbsp;weeks compared to the 8&nbsp;weeks prior to baseline).</p><p>&nbsp;</p><p>Median time from baseline to first transfusion was statistically significantly longer in the epoetin alfa group compared to placebo (49 vs. 37&nbsp;days; p=0.046). After 4&nbsp;weeks of treatment the time to first transfusion was further increased in the epoetin alfa group (142 vs. 50&nbsp;days, p=0.007). The percentage of subjects who were transfused in the epoetin alfa group decreased from 51.8% in the 8&nbsp;weeks prior to baseline to 24.7% between weeks&nbsp;16 and 24, compared to the placebo group which had an increase in transfusion rate from 48.9% to 54.1% over the same time periods.</p><p><strong><em>&nbsp;</em></strong></p><p><u>Paediatric population</u></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em>Chronic Renal Failure</em></strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p>Epoetin alfa was evaluated in an open-label, non-randomised, open dose-range, 52-week clinical study in paediatric CRF patients undergoing haemodialysis. The median age of patients enrolled in the study was 11.6&nbsp;years (range 0.5 to 20.1&nbsp;years).</p><p>&nbsp;</p><p>Epoetin alfa was administered at 75&nbsp;IU/kg/week intravenously in 2 or 3 divided doses post-dialysis, titrated by 75&nbsp;IU/kg/week at intervals of 4&nbsp;weeks (up to a maximum of 300&nbsp;IU/kg/week), to achieve a 1&nbsp;g/dL/month increase in haemoglobin. The desired haemoglobin concentration range was 9.6 to 11.2&nbsp;g/dL. Eighty-one percent of patients achieved the haemoglobin concentration level. The median time to target was 11&nbsp;weeks and the median dose at target was 150&nbsp;IU/kg/week. Of the patients who achieved the target, 90% did so on a 3&nbsp;times-per-week dosing regimen.</p><p>&nbsp;</p><p>After 52&nbsp;weeks, 57% of patients remained in the study, receiving a median dose of 200&nbsp;IU/kg/week.</p><p>&nbsp;</p><p>Clinical data with subcutaneous administration in children are limited. In 5 small, open label, uncontrolled studies (number of patients ranged from 9-22, total N=72), Epoetin alfa has been administered subcutaneously in children at starting doses of 100&nbsp;IU/kg/week to 150&nbsp;IU/kg/week with the possibility to increase up to 300&nbsp;IU/kg/week. In these studies, most were predialysis patients (N=44), 27 patients were on peritoneal dialysis and 2 were on haemodialysis with age ranging from 4 months to 17 years. Overall, these studies have methodological limitations but treatment was associated with positive trends towards higher haemoglobin levels. No unexpected adverse events were reported (see section 4.2).</p><p>&nbsp;</p><p><strong><em>Chemotherapy-induced anaemia</em></strong></p><p>&nbsp;</p><p>Epoetin alfa 600&nbsp;IU/kg (administered intravenously or subcutaneously once weekly) has been evaluated in a randomised, double-blind, placebo-controlled, 16-week study and in a randomised, controlled, open-label, 20-week study in anaemic paediatric patients receiving myelosuppressive chemotherapy for the treatment of various childhood non-myeloid malignancies.</p><p>&nbsp;</p><p>In the 16-week study (n=222), in the epoetin alfa-treated patients there was no statistically significant effect on patient-reported or parent-reported Paediatric Quality of Life Inventory or Cancer Module scores compared with placebo (primary efficacy endpoint). In addition, there was no statistical difference between the proportion of patients requiring pRBC transfusions between the Epoetin alfa group and placebo.</p><p>&nbsp;</p><p>In the 20-week study (n=225), no significant difference was observed in the primary efficacy endpoint, i.e. the proportion of patients who required a RBC transfusion after Day 28 (62% of epoetin alfa patients versus 69% of standard therapy patients).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p><strong><em>&nbsp;</em></strong></p><p>Following subcutaneous injection, serum levels of epoetin alfa reach a peak between 12 and 18&nbsp;hours post-dose. There was no accumulation after multiple dose administration of 600&nbsp;IU/kg administered subcutaneously weekly.</p><p>&nbsp;</p><p>The absolute bioavailability of subcutaneous injectable epoetin alfa is approximately 20% in healthy subjects.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><strong><em>&nbsp;</em></strong></p><p>The mean volume of distribution was 49.3&nbsp;mL/kg after intravenous doses of 50 and 100&nbsp;IU/kg in healthy subjects. Following intravenous administration of epoetin alfa in subjects with chronic renal failure, the volume of distribution ranged from 57-107&nbsp;mL/kg after single dosing (12&nbsp;IU/kg) to 42-64&nbsp;mL/kg after multiple dosing (48-192&nbsp;IU/kg), respectively. Thus, the volume of distribution is slightly greater than the plasma space.</p><p>&nbsp;</p><p><u>Elimination</u></p><p><strong><em>&nbsp;</em></strong></p><p>The half-life of epoetin alfa following multiple dose intravenous administration is approximately 4&nbsp;hours in healthy subjects. The half-life for the subcutaneous route is estimated to be approximately 24&nbsp;hours in healthy subjects.</p><p>&nbsp;</p><p>The mean CL/F for the 150&nbsp;IU/kg 3 times-per-week and 40,000&nbsp;IU once-weekly regimens in healthy subjects were 31.2 and 12.6&nbsp;mL/h/kg, respectively. The mean CL/F for the 150&nbsp;IU/kg, 3-times-per-week and 40,000&nbsp;IU, once-weekly regimens in the anaemic cancer subjects were 45.8 and 11.3&nbsp;mL/h/kg, respectively. In most anaemic subjects with cancer receiving cyclic chemotherapy CL/F was lower after subcutaneous doses of 40,000&nbsp;IU once&nbsp;weekly and 150&nbsp;IU/kg, 3 times per week compared with the values for healthy subjects.</p><p><strong>&nbsp;</strong></p><p><u>Linearity/non-linearity</u></p><p><strong><em>&nbsp;</em></strong></p><p>In healthy subjects, a dose‑proportional increase in serum epoetin alfa concentrations was observed after intravenous administration of 150 and 300&nbsp;IU/kg, 3 times per week. Administration of single doses of 300 to 2,400&nbsp;IU/kg subcutaneous epoetin alfa resulted in a linear relationship between mean C<sub>max</sub> and dose and between mean AUC and dose. An inverse relationship between apparent clearance and dose was noted in healthy subjects.</p><p>&nbsp;</p><p>In studies to explore extending the dosing interval (40,000&nbsp;IU once weekly and 80,000, 100,000, and 120,000&nbsp;IU biweekly), a linear but non‑dose‑proportional relationship was observed between mean C<sub>max</sub> and dose, and between mean AUC and dose at steady state.</p><p><strong>&nbsp;</strong></p><p><u>Pharmacokinetic/pharmacodynamic relationships</u></p><p><strong><em>&nbsp;</em></strong></p><p>Epoetin alfa exhibits a dose-related effect on haematological parameters which is independent of route of administration.</p><p><strong>&nbsp;</strong></p><p><strong><em>Paediatric population</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>A half-life of approximately 6.2 to 8.7&nbsp;hours has been reported in paediatric subjects with chronic renal failure following multiple dose intravenous administration of epoetin alfa. The pharmacokinetic profile of epoetin alfa in children and adolescents appears to be similar to that of adults.</p><p><strong>&nbsp;</strong></p><p>Pharmacokinetic data in neonates is limited.</p><p>&nbsp;</p><p>A study of 7 preterm very low birth weight neonates and 10 healthy adults given i.v. erythropoietin suggested that distribution volume was approximately 1.5 to 2 times higher in the preterm neonates than in the healthy adults, and clearance was approximately 3 times higher in the preterm neonates than in healthy adults.</p><p><strong>&nbsp;</strong></p><p><strong><em>Renal impairment</em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>In chronic renal failure patients, the half-life of intravenously administered epoetin alfa is slightly prolonged, approximately 5&nbsp;hours, compared to healthy subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeated dose toxicological studies in dogs and rats, but not in monkeys, epoetin alfa therapy was associated with subclinical bone marrow fibrosis. Bone marrow fibrosis is a known complication of chronic renal failure in humans and may be related to secondary hyperparathyroidism or unknown factors. The incidence of bone marrow fibrosis was not increased in a study of haemodialysis patients who were treated with epoetin alfa for 3&nbsp;years compared to a matched control group of dialysis patients who had not been treated with epoetin alfa.</p><p>&nbsp;</p><p>Epoetin alfa does not induce bacterial gene mutation (Ames Test), chromosomal aberrations in mammalian cells, micronuclei in mice, or gene mutation at the HGPRT locus.</p><p>&nbsp;</p><p>Long-term carcinogenicity studies have not been carried out. Conflicting reports in the literature, based on <em>in vitro</em> findings from human tumour samples, suggest erythropoietins may play a role as tumour proliferators. This is of uncertain significance in the clinical situation.</p><p>&nbsp;</p><p>In cell cultures of human bone marrow cells, epoetin alfa stimulates erythropoiesis specifically and does not affect leucopoiesis. Cytotoxic actions of epoetin alfa on bone marrow cells could not be detected.</p><p>&nbsp;</p><p>In animal studies, epoetin alfa has been shown to decrease foetal body weight, delay ossification and increase foetal mortality when given in weekly doses of approximately 20&nbsp;times the recommended human weekly dose. These changes are interpreted as being secondary to decreased maternal body weight gain, and the significance to humans is unknown given therapeutic dose levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polysorbate 80</p><p>Glycine</p><p>Water for injections</p><p>Sodium dihydrogen phosphate dihydrate</p><p>Disodium phosphate dihydrate</p><p>Sodium chloride</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                18 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator<strong> </strong>(2&deg;C to 8&deg;C). This temperature range should be closely maintained until administration to the patient. Store in the original package in order to protect from light. Do not freeze or shake.</p><p>&nbsp;</p><p>For the purpose of ambulatory use, the product may be taken out of the refrigerator, without being replaced, for a maximum period of 3&nbsp;days at a temperature not above 25&deg;C. If the medicine has not been used at the end of this period, it should be disposed of.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>EPREX, ERYPO 2,000&nbsp;IU/mL solution for injection in pre-filled syringe</u></p><p>0.5&nbsp;mL (1,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p><u>EPREX, ERYPO 4,000&nbsp;IU/mL solution for injection in pre-filled syringe</u></p><p>0.5&nbsp;mL (2,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p><u>EPREX, ERYPO 10,000&nbsp;IU/mL solution for injection in pre-filled syringe</u></p><p>0.3&nbsp;mL (3,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS<sup>&trade;</sup> needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p>0.4&nbsp;mL (4,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p>0.5&nbsp;mL (5,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p>0.6&nbsp;mL (6,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p>0.8&nbsp;mL (8,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6.</p><p>&nbsp;</p><p>1.0&nbsp;mL (10,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack size of 6</p><p>&nbsp;</p><p><u>EPREX, ERYPO 40,000&nbsp;IU/mL solution for injection in pre-filled syringe</u></p><p>0.5&nbsp;mL (20,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack sizes of 1,4 or 6.</p><p>&nbsp;</p><p>0.75&nbsp;mL (30,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack sizes of 1,4 or 6.</p><p>&nbsp;</p><p>1.0&nbsp;mL (40,000&nbsp;IU) of solution for injection in a pre-filled syringe (type I glass) with plunger (Teflon-faced rubber) and needle with a needle shield (rubber with polypropylene cover) and a PROTECS&trade; needle guard device (polycarbonate) attached to the syringe - pack sizes of 1,4 or 6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The product should not be used, and discarded</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the seal is broken,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the liquid is coloured or you can see particles floating in it,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you know, or think that it may have been accidentally frozen, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if there has been a refrigerator failure.</p><p>&nbsp;</p><p>The product is for single use only. Only take one dose of EPREX, ERYPO from each syringe. In case only a partial dose of the syringe is required, the cover should be removed before the plunger is pushed up to the desired numbered graduation mark to remove unwanted solution before injection. Refer to section&nbsp;3. How to use EPREX, ERYPO (instructions on how to inject EPREX, ERYPO) of the package leaflet.</p><p>&nbsp;</p><p>The pre-filled syringes are fitted with the PROTECS<sup>&trade;</sup> needle guard device to help prevent needle stick injuries after use. The package leaflet includes full instructions for the use and handling of pre-filled syringes with the PROTECS<sup>&trade;</sup> needle guard.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer: 
See outer carton  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April  2016. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>